WO1996026953A1 - FsF-1 ET LA DETECTION PRECOCE DES FIBROSES - Google Patents
FsF-1 ET LA DETECTION PRECOCE DES FIBROSES Download PDFInfo
- Publication number
- WO1996026953A1 WO1996026953A1 PCT/US1996/002726 US9602726W WO9626953A1 WO 1996026953 A1 WO1996026953 A1 WO 1996026953A1 US 9602726 W US9602726 W US 9602726W WO 9626953 A1 WO9626953 A1 WO 9626953A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fsf
- polypeptide
- fibrosin
- cells
- human
- Prior art date
Links
- 108010048500 fibroblast stimulating factor-1 Proteins 0.000 title claims abstract description 220
- 206010016654 Fibrosis Diseases 0.000 title claims abstract description 36
- 230000004761 fibrosis Effects 0.000 title claims abstract description 36
- 238000001514 detection method Methods 0.000 title description 8
- 238000000034 method Methods 0.000 claims abstract description 70
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 24
- 230000001575 pathological effect Effects 0.000 claims abstract description 24
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 16
- 208000037976 chronic inflammation Diseases 0.000 claims abstract description 10
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims abstract description 10
- 210000004027 cell Anatomy 0.000 claims description 145
- 210000002950 fibroblast Anatomy 0.000 claims description 139
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 110
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 81
- 229920001184 polypeptide Polymers 0.000 claims description 80
- 239000006228 supernatant Substances 0.000 claims description 70
- 108020004414 DNA Proteins 0.000 claims description 57
- 210000004408 hybridoma Anatomy 0.000 claims description 43
- 241001529936 Murinae Species 0.000 claims description 33
- 238000004519 manufacturing process Methods 0.000 claims description 33
- 210000002966 serum Anatomy 0.000 claims description 29
- 150000007523 nucleic acids Chemical group 0.000 claims description 26
- 239000000523 sample Substances 0.000 claims description 25
- 102000053602 DNA Human genes 0.000 claims description 20
- 230000035755 proliferation Effects 0.000 claims description 18
- 108010067306 Fibronectins Proteins 0.000 claims description 17
- 238000002360 preparation method Methods 0.000 claims description 16
- 102000008186 Collagen Human genes 0.000 claims description 15
- 108010035532 Collagen Proteins 0.000 claims description 15
- 229920001436 collagen Polymers 0.000 claims description 15
- 238000010790 dilution Methods 0.000 claims description 15
- 239000012895 dilution Substances 0.000 claims description 15
- 230000014509 gene expression Effects 0.000 claims description 15
- 206010039710 Scleroderma Diseases 0.000 claims description 14
- 201000004409 schistosomiasis Diseases 0.000 claims description 13
- 230000037390 scarring Effects 0.000 claims description 10
- 238000010367 cloning Methods 0.000 claims description 9
- 230000000692 anti-sense effect Effects 0.000 claims description 8
- 230000003399 chemotactic effect Effects 0.000 claims description 8
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 7
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 7
- 210000002744 extracellular matrix Anatomy 0.000 claims description 7
- 229940099552 hyaluronan Drugs 0.000 claims description 7
- 229920002674 hyaluronan Polymers 0.000 claims description 7
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 claims description 7
- 239000012472 biological sample Substances 0.000 claims description 6
- 206010019668 Hepatic fibrosis Diseases 0.000 claims description 5
- 230000004936 stimulating effect Effects 0.000 claims description 5
- 241001465754 Metazoa Species 0.000 claims description 4
- 108020004511 Recombinant DNA Proteins 0.000 claims description 4
- 230000003472 neutralizing effect Effects 0.000 claims description 4
- 201000000306 sarcoidosis Diseases 0.000 claims description 4
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims description 3
- 230000035876 healing Effects 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 208000010157 sclerosing cholangitis Diseases 0.000 claims description 3
- 210000002700 urine Anatomy 0.000 claims description 3
- 108091033380 Coding strand Proteins 0.000 claims description 2
- 230000033001 locomotion Effects 0.000 claims description 2
- 102000016359 Fibronectins Human genes 0.000 claims 1
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 210000005228 liver tissue Anatomy 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 108010093597 fibrosin Proteins 0.000 description 169
- 102100029532 Probable fibrosin-1 Human genes 0.000 description 167
- 206010018691 Granuloma Diseases 0.000 description 86
- 108090000623 proteins and genes Proteins 0.000 description 57
- 102000004169 proteins and genes Human genes 0.000 description 54
- 235000018102 proteins Nutrition 0.000 description 51
- 239000012228 culture supernatant Substances 0.000 description 50
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 46
- 239000002299 complementary DNA Substances 0.000 description 46
- 210000004698 lymphocyte Anatomy 0.000 description 40
- 230000004044 response Effects 0.000 description 39
- 238000003556 assay Methods 0.000 description 38
- 241000283973 Oryctolagus cuniculus Species 0.000 description 37
- 235000001014 amino acid Nutrition 0.000 description 35
- 235000013601 eggs Nutrition 0.000 description 34
- 229940024606 amino acid Drugs 0.000 description 33
- 238000002474 experimental method Methods 0.000 description 33
- 239000003636 conditioned culture medium Substances 0.000 description 32
- 241000699670 Mus sp. Species 0.000 description 31
- 150000001413 amino acids Chemical class 0.000 description 31
- 230000000694 effects Effects 0.000 description 30
- 230000002297 mitogenic effect Effects 0.000 description 30
- 241000699666 Mus <mouse, genus> Species 0.000 description 29
- 230000004071 biological effect Effects 0.000 description 27
- 229920002684 Sepharose Polymers 0.000 description 24
- 239000002773 nucleotide Substances 0.000 description 24
- 125000003729 nucleotide group Chemical group 0.000 description 24
- 239000011780 sodium chloride Substances 0.000 description 24
- 238000002965 ELISA Methods 0.000 description 23
- 210000001744 T-lymphocyte Anatomy 0.000 description 23
- 239000003226 mitogen Substances 0.000 description 23
- 239000000047 product Substances 0.000 description 23
- 238000011282 treatment Methods 0.000 description 22
- 239000013612 plasmid Substances 0.000 description 21
- 239000002609 medium Substances 0.000 description 20
- 239000000203 mixture Substances 0.000 description 19
- 210000002381 plasma Anatomy 0.000 description 19
- 239000012634 fragment Substances 0.000 description 18
- 108020004707 nucleic acids Proteins 0.000 description 18
- 102000039446 nucleic acids Human genes 0.000 description 18
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 17
- 230000003352 fibrogenic effect Effects 0.000 description 17
- 229920000669 heparin Polymers 0.000 description 17
- 229960002897 heparin Drugs 0.000 description 17
- 238000003786 synthesis reaction Methods 0.000 description 17
- 239000013598 vector Substances 0.000 description 17
- 108010062580 Concanavalin A Proteins 0.000 description 16
- 102100037362 Fibronectin Human genes 0.000 description 16
- 241000700159 Rattus Species 0.000 description 16
- 230000002378 acidificating effect Effects 0.000 description 16
- 238000011534 incubation Methods 0.000 description 16
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 16
- 241000283707 Capra Species 0.000 description 15
- 125000003275 alpha amino acid group Chemical group 0.000 description 15
- 238000001516 cell proliferation assay Methods 0.000 description 15
- 101000624643 Homo sapiens M-phase inducer phosphatase 3 Proteins 0.000 description 14
- 101000580039 Homo sapiens Ras-specific guanine nucleotide-releasing factor 1 Proteins 0.000 description 14
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 14
- 102100023330 M-phase inducer phosphatase 3 Human genes 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 14
- 238000010348 incorporation Methods 0.000 description 14
- 208000015181 infectious disease Diseases 0.000 description 14
- 239000000463 material Substances 0.000 description 14
- 108020004999 messenger RNA Proteins 0.000 description 14
- 230000035605 chemotaxis Effects 0.000 description 13
- 230000000638 stimulation Effects 0.000 description 13
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 12
- 230000012010 growth Effects 0.000 description 12
- 241000242680 Schistosoma mansoni Species 0.000 description 11
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 11
- 229960002591 hydroxyproline Drugs 0.000 description 11
- 238000000338 in vitro Methods 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 11
- 238000001262 western blot Methods 0.000 description 11
- 108020004705 Codon Proteins 0.000 description 10
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 10
- 230000027455 binding Effects 0.000 description 10
- 239000000872 buffer Substances 0.000 description 10
- 238000005119 centrifugation Methods 0.000 description 10
- 210000004185 liver Anatomy 0.000 description 10
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 9
- 239000012980 RPMI-1640 medium Substances 0.000 description 9
- 239000000427 antigen Substances 0.000 description 9
- 108091007433 antigens Proteins 0.000 description 9
- 102000036639 antigens Human genes 0.000 description 9
- 239000011324 bead Substances 0.000 description 9
- -1 ethotrexate Substances 0.000 description 9
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 9
- 239000000499 gel Substances 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- 238000006386 neutralization reaction Methods 0.000 description 9
- 241000283690 Bos taurus Species 0.000 description 8
- 208000011231 Crohn disease Diseases 0.000 description 8
- 239000000020 Nitrocellulose Substances 0.000 description 8
- 238000001042 affinity chromatography Methods 0.000 description 8
- 238000010828 elution Methods 0.000 description 8
- 238000000684 flow cytometry Methods 0.000 description 8
- 238000002523 gelfiltration Methods 0.000 description 8
- 230000002440 hepatic effect Effects 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 229920001220 nitrocellulos Polymers 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- 239000012679 serum free medium Substances 0.000 description 8
- 238000010186 staining Methods 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- 102000004127 Cytokines Human genes 0.000 description 7
- 108090000695 Cytokines Proteins 0.000 description 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 7
- ZWPRYVATYZPCDP-UHFFFAOYSA-M bis(dibutylamino)methylidene-dibutylazanium;fluoride Chemical compound [F-].CCCCN(CCCC)C(N(CCCC)CCCC)=[N+](CCCC)CCCC ZWPRYVATYZPCDP-UHFFFAOYSA-M 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 208000019425 cirrhosis of liver Diseases 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 6
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 6
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 102000004388 Interleukin-4 Human genes 0.000 description 6
- 108090000978 Interleukin-4 Proteins 0.000 description 6
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 6
- 108700026244 Open Reading Frames Proteins 0.000 description 6
- 230000000347 anti-schistosomal effect Effects 0.000 description 6
- 238000004587 chromatography analysis Methods 0.000 description 6
- 210000004748 cultured cell Anatomy 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000001962 electrophoresis Methods 0.000 description 6
- 230000003176 fibrotic effect Effects 0.000 description 6
- 238000001641 gel filtration chromatography Methods 0.000 description 6
- 230000003053 immunization Effects 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 238000013508 migration Methods 0.000 description 6
- 230000005012 migration Effects 0.000 description 6
- 238000010561 standard procedure Methods 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- 238000001890 transfection Methods 0.000 description 6
- 230000014616 translation Effects 0.000 description 6
- 238000011144 upstream manufacturing Methods 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 102000012422 Collagen Type I Human genes 0.000 description 5
- 108010022452 Collagen Type I Proteins 0.000 description 5
- 102000029816 Collagenase Human genes 0.000 description 5
- 108060005980 Collagenase Proteins 0.000 description 5
- 206010020751 Hypersensitivity Diseases 0.000 description 5
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 5
- 108010074338 Lymphokines Proteins 0.000 description 5
- 102000008072 Lymphokines Human genes 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 5
- 208000026935 allergic disease Diseases 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- 230000000903 blocking effect Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000001684 chronic effect Effects 0.000 description 5
- 229960002424 collagenase Drugs 0.000 description 5
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 5
- 230000013595 glycosylation Effects 0.000 description 5
- 238000006206 glycosylation reaction Methods 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 230000009610 hypersensitivity Effects 0.000 description 5
- 238000001114 immunoprecipitation Methods 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 5
- 230000000644 propagated effect Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 4
- 239000004475 Arginine Substances 0.000 description 4
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 4
- 108020004635 Complementary DNA Proteins 0.000 description 4
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 4
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 4
- 208000037581 Persistent Infection Diseases 0.000 description 4
- 239000004743 Polypropylene Substances 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 230000002491 angiogenic effect Effects 0.000 description 4
- 230000000507 anthelmentic effect Effects 0.000 description 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 230000008021 deposition Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000002500 effect on skin Effects 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 230000028709 inflammatory response Effects 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 210000001616 monocyte Anatomy 0.000 description 4
- 229920001155 polypropylene Polymers 0.000 description 4
- 230000000750 progressive effect Effects 0.000 description 4
- 238000001243 protein synthesis Methods 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 230000004043 responsiveness Effects 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 210000004988 splenocyte Anatomy 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 210000002437 synoviocyte Anatomy 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 3
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 241000601170 Clematis lasiantha Species 0.000 description 3
- 238000012286 ELISA Assay Methods 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 3
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 3
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 208000030852 Parasitic disease Diseases 0.000 description 3
- 108010004729 Phycoerythrin Proteins 0.000 description 3
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 3
- 241000242678 Schistosoma Species 0.000 description 3
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 230000006427 angiogenic response Effects 0.000 description 3
- 238000005349 anion exchange Methods 0.000 description 3
- 230000003510 anti-fibrotic effect Effects 0.000 description 3
- 239000006286 aqueous extract Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000001851 biosynthetic effect Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 230000003828 downregulation Effects 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 230000007717 exclusion Effects 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 230000033687 granuloma formation Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000009696 proliferative response Effects 0.000 description 3
- 239000013014 purified material Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 229910052709 silver Inorganic materials 0.000 description 3
- 239000004332 silver Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 230000003393 splenic effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 238000009010 Bradford assay Methods 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 201000003066 Diffuse Scleroderma Diseases 0.000 description 2
- 206010063045 Effusion Diseases 0.000 description 2
- 206010018364 Glomerulonephritis Diseases 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 208000024815 Granulomatous liver disease Diseases 0.000 description 2
- 102100031000 Hepatoma-derived growth factor Human genes 0.000 description 2
- 101001083798 Homo sapiens Hepatoma-derived growth factor Proteins 0.000 description 2
- 241001174911 Iasis Species 0.000 description 2
- 108010002586 Interleukin-7 Proteins 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 208000002848 Schistosomiasis mansoni Diseases 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 201000009594 Systemic Scleroderma Diseases 0.000 description 2
- 206010042953 Systemic sclerosis Diseases 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 239000002870 angiogenesis inducing agent Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000002051 biphasic effect Effects 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 229960001338 colchicine Drugs 0.000 description 2
- 210000004087 cornea Anatomy 0.000 description 2
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000003979 eosinophil Anatomy 0.000 description 2
- ZFKJVJIDPQDDFY-UHFFFAOYSA-N fluorescamine Chemical compound C12=CC=CC=C2C(=O)OC1(C1=O)OC=C1C1=CC=CC=C1 ZFKJVJIDPQDDFY-UHFFFAOYSA-N 0.000 description 2
- 238000005534 hematocrit Methods 0.000 description 2
- 231100000843 hepatic granuloma Toxicity 0.000 description 2
- 208000017694 hepatic granuloma Diseases 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 239000000413 hydrolysate Substances 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 238000007901 in situ hybridization Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229960004452 methionine Drugs 0.000 description 2
- RFKMCNOHBTXSMU-UHFFFAOYSA-N methoxyflurane Chemical compound COC(F)(F)C(Cl)Cl RFKMCNOHBTXSMU-UHFFFAOYSA-N 0.000 description 2
- 229960002455 methoxyflurane Drugs 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- FSVCQIDHPKZJSO-UHFFFAOYSA-L nitro blue tetrazolium dichloride Chemical compound [Cl-].[Cl-].COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 FSVCQIDHPKZJSO-UHFFFAOYSA-L 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 230000030393 positive regulation of fibroblast proliferation Effects 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 230000014621 translational initiation Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- HBOMLICNUCNMMY-KJFJCRTCSA-N 1-[(4s,5s)-4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1C1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-KJFJCRTCSA-N 0.000 description 1
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- FSVJFNAIGNNGKK-UHFFFAOYSA-N 2-[cyclohexyl(oxo)methyl]-3,6,7,11b-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-4-one Chemical compound C1C(C2=CC=CC=C2CC2)N2C(=O)CN1C(=O)C1CCCCC1 FSVJFNAIGNNGKK-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 238000010600 3H thymidine incorporation assay Methods 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- LVLOFXJWZQNNRX-UHFFFAOYSA-N 4-methylaniline;phosphoric acid Chemical compound OP(O)(O)=O.CC1=CC=C(N)C=C1 LVLOFXJWZQNNRX-UHFFFAOYSA-N 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 102100030009 Azurocidin Human genes 0.000 description 1
- 101710154607 Azurocidin Proteins 0.000 description 1
- 206010004659 Biliary cirrhosis Diseases 0.000 description 1
- 108700031361 Brachyury Proteins 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 229920000298 Cellophane Polymers 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- 240000006497 Dianthus caryophyllus Species 0.000 description 1
- 235000009355 Dianthus caryophyllus Nutrition 0.000 description 1
- 101000609767 Dromaius novaehollandiae Ovalbumin Proteins 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 108010034145 Helminth Proteins Proteins 0.000 description 1
- 208000015336 Helminthic disease Diseases 0.000 description 1
- 101800001649 Heparin-binding EGF-like growth factor Proteins 0.000 description 1
- 102400001369 Heparin-binding EGF-like growth factor Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000871708 Homo sapiens Proheparin-binding EGF-like growth factor Proteins 0.000 description 1
- 108010058683 Immobilized Proteins Proteins 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 235000013878 L-cysteine Nutrition 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- 229930195722 L-methionine Natural products 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 101710173438 Late L2 mu core protein Proteins 0.000 description 1
- 229920005479 Lucite® Polymers 0.000 description 1
- 102100030856 Myoglobin Human genes 0.000 description 1
- 108010062374 Myoglobin Proteins 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoryl-L-serine Natural products OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 241001111421 Pannus Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 108091036407 Polyadenylation Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102100033762 Proheparin-binding EGF-like growth factor Human genes 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 241000242677 Schistosoma japonicum Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 208000010513 Stupor Diseases 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 101100220533 Zea mays CPN60I gene Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 238000011256 aggressive treatment Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 108010027597 alpha-chymotrypsin Proteins 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 210000001742 aqueous humor Anatomy 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000021523 carboxylation Effects 0.000 description 1
- 238000006473 carboxylation reaction Methods 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 239000002975 chemoattractant Substances 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000037319 collagen production Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 210000003683 corneal stroma Anatomy 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229950006137 dexfosfoserine Drugs 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000001400 expression cloning Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000003953 foreskin Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000001279 glycosylating effect Effects 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 208000010758 granulomatous inflammation Diseases 0.000 description 1
- 244000000013 helminth Species 0.000 description 1
- 210000005104 human peripheral blood lymphocyte Anatomy 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000007233 immunological mechanism Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000011694 lewis rat Methods 0.000 description 1
- 238000007834 ligase chain reaction Methods 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 239000000891 luminescent agent Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000001617 migratory effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000004768 organ dysfunction Effects 0.000 description 1
- 230000003349 osteoarthritic effect Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 230000017448 oviposition Effects 0.000 description 1
- 150000004995 p-toluidines Chemical class 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 108010091748 peptide A Proteins 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 238000003359 percent control normalization Methods 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
- USRGIUJOYOXOQJ-GBXIJSLDSA-N phosphothreonine Chemical compound OP(=O)(O)O[C@H](C)[C@H](N)C(O)=O USRGIUJOYOXOQJ-GBXIJSLDSA-N 0.000 description 1
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical group OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 210000004910 pleural fluid Anatomy 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 208000007232 portal hypertension Diseases 0.000 description 1
- 230000030786 positive chemotaxis Effects 0.000 description 1
- 230000030503 positive regulation of chemotaxis Effects 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 235000008476 powdered milk Nutrition 0.000 description 1
- 229960002957 praziquantel Drugs 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- INCIMLINXXICKS-UHFFFAOYSA-M pyronin Y Chemical compound [Cl-].C1=CC(=[N+](C)C)C=C2OC3=CC(N(C)C)=CC=C3C=C21 INCIMLINXXICKS-UHFFFAOYSA-M 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 229940083575 sodium dodecyl sulfate Drugs 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 208000008732 thymoma Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the field of the invention is lymphokines and fibrosis.
- Schistosomiasis is one of the most prominent helminthic diseases, estimated to afflict 200 million people in the tropics (Walsh et al., 1979).
- Two of the schistosome species that infect humans can cause serious morbidity (including portal hypertension and gastrointestinal hemorrhage) as a result of a form of hepatic fibrosis
- infected individuals may aid the prevention of scarring.
- anti-inflammatory or immunosuppressive drugs including ethotrexate, cytotoxins, and various corticosteriods may aid the prevention of scarring.
- these drugs are known to produce a number of relatively severe side effects, treatment of all infected individuals, 94-97% of which would never develop the progressive fibrotic form of the disease, is both undesirable and impractical.
- Several other chronic inflammatory diseases including pulmonary fibrosis, scleroderma/progressive systemic sclerosis, sarcoidosis, sclerosing cholangitis, primary biliary cirrhosis, and inflammatory bowel disease also can result in organ dysfunction due to pathological fibrosis.
- FsF-1 also referred to as fibrosin
- fibrosin is a novel lymphokine that is a heparin-binding growth factor. It stimulates fibroblast proliferation, collagen and hyaluronan synthesis, and acts as a chemoattractant for fibroblasts.
- FsF-1/fibrosin is distinct from other previously characterized heparin-binding growth factors.
- the invention features a substantially pure FsF-1 polypeptide.
- This polypeptide may be encoded by mammalian DNA, such as that of a mouse or a human.
- human FsF-1 is meant the polypeptide encoded by the DNA sequence of SEQ ID NO.:11.
- murine FsF-1 is meant the polypeptide encoded by the DNA sequence of SEQ ID NO. :2.
- polypeptide is meant any chain of amino acids, regardless of length or post-translational modification (e.g., glycosylation) .
- An FsF-1 polypeptide is preferably a polypeptide having one or more of the biological activities of human FsF-1.
- these activities include stimulation of fibroblast proliferation, stimulation of fibronectin, collagen, and hyaluronan synthesis, and chemoattraction.
- the invention also includes biologically active polypeptide fragments or analogs of the FsF-1 of the invention.
- biologically active is meant possessing any in vivo or in vitro activity that is characteristic of the FsF-1 of the invention as assayed by the methods described herein.
- a biologically active FsF-l polypeptide or polypeptide fragment generally possesses at least 40%, more preferably at least 70%, and most preferably at least 90% of the activity of human FsF-1 described herein.
- a biologically active FsF-1 polypeptide may also have activity that is 30%, 50%, 70%, 80%, or 90% of the activity of the human or murine FsF-1 2B3 domain.
- a biologically active FsF-1 polypeptide may also have activity that is 30%, 50%, 70%, 80%, or 90% of the activity of a subdomain of the human or murine FsF-1 2B3 domain, such as 2B3a or 2B3b.
- 2B3 domain of FsF- 1 is meant that portion of FsF-1 corresponding to amino acids 26 (Arg encoded by AGG) to 96 (Leu encoded by CTA) of murine FSF-1 (SEQ ID N0.:1).
- the "2B3 domain of human FsF-1” corresponds to the 71 amino acid polypeptide of the murine 2B3 domain of FsF-1 shown in SEQ ID N0.:1.
- the 2B3 domain of human FsF-1 is encoded by nucleotides within the human FsF-1 cDNA sequence of SEQ ID NO.:11 beginning a nucleotide 318 (codon AGG) .
- the 2B3 domain has been further divided into the subdomains, 2B3a and 2B3b.
- 2B3a subdomain is meant polypeptides 26-45 of SEQ ID N0.:1.
- 2B3b subdomain is meant polypeptides 46-96 of SEQ ID N0.:1.
- the 2B3 domain exhibits comparable activity to full-length fibrosin in a cellular proliferation assay, such as the fibroblast proliferation assay described herein.
- the polypeptide of the invention may be immuno- purified from the supernatant of granuloma cultures, or from the serum of a mammal, such a mouse or a human.
- the polypeptide of the invention may be a synthetic polypeptide.
- the invention also includes an FsF-1 polypeptide, FsF-1 polypeptide fragments, or analogs of FsF-1 that function as antagonists of the FsF-1 receptor.
- the invention features isolated DNA consisting essentially of a DNA sequence encoding an FsF-1 polypeptide, or a fragment of the FsF-1 polypeptide such as the 2B3 domain, the 2B3a subdomain, or the 2B3b subdomain.
- isolated is meant a DNA that is not immediately contiguous with (i.e., covalently linked to) both of the coding sequences with which it is immediately contiguous in the naturally occurring genome of the organism from which the DNA of the invention is derived.
- the term therefore includes, for example, a recombinant DNA which is incorporated into a vector (e.g., an autonomously replicating virus or plasmid) , or into the genomic DNA of a prokaryote or eukaryote; DNA which exists as a separate molecule independent of other DNA sequences such as a cDNA or genomic DNA fragment produced by chemical means (e.g.
- the isolated DNAs of the invention are single-stranded DNAs that are generally at least 10 nucleotides long, preferably at least 18 nucleotides long, more preferably at least 30 nucleotides long, and ranging up to full-length of the gene or cDNA encoding an FsF-1 polypeptide.
- the single- stranded DNAs can also be detectably labelled for use as hybridization probes, and can be antisense.
- the isolated DNA hybridizes under conditions of high stringency to a nucleic acid having the sequence of Fig. 25 (SEQ ID N0.:2) or Fig. 26 (SEQ ID NO.:3) .
- high stringency is meant, for example, conditions such as those described herein below for the isolation of human FsF-1 cDNA (also see Current Protocols in Molecular Biology, John Wiley & Sons, New York, 1989) .
- the DNA of the invention can be incorporated into a vector [which may be provided as a purified preparation (e.g., a vector separated from the mixture of vectors which make up a library) ] containing a DNA sequence encoding an FsF-1 polypeptide of the invention or a fragment of the FsF-1 polypeptide, and a cell or essentially homogeneous population of cells (e.g. prokaryotic cells, or eukaryotic cells such as mammalian cells) which contain the vector or the isolated DNA described above.
- a vector which may be provided as a purified preparation (e.g., a vector separated from the mixture of vectors which make up a library) ] containing a DNA sequence encoding an FsF-1 polypeptide of the invention or a fragment of the FsF-1 polypeptide, and a cell or essentially homogeneous population of cells (e.g. prokaryotic cells, or eukaryotic cells such as mammalian cells) which contain the vector or the
- essentially homogeneous population of cells is meant that at least 99% of the cells contain the vector of the invention (or the isolated DNA) .
- the vector is capable of directing expression of an FsF-1 polypeptide (for example, in a cell transfected or transformed with the vector) .
- a nucleic acid "consisting essentially of" a particular sequence of nucleotides as used herein refers to that particular sequence and other sequences that are the same as the first sequence but for the addition to or removal from the sequence of a few nucleotides (e.g., 2 to 10) which does not alter the amino acid sequence encoded by the nucleic acid.
- Similarity refers to the subunit sequence similarity between two molecules. When a subunit position in both of the molecules is occupied by the same onomeric subunit (i.e., the same nucleotide or amino acid, respectively) , then the molecules are the same at that position.
- the similarity between two nucleotide or two amino acid sequences is a direct function of the number of matching or homologous positions, e.g., if half the positions in two DNA or two amino acid sequences are the same, then the sequences are 50% similar.
- substantially similar is meant a polypeptide or nucleic acid that is at least 60%, preferably 75%, more preferably 80%, and most preferably 95% the same as a reference amino acid or nucleic acid sequence.
- the length of comparison sequences will generally be at least 16 amino acids, preferably at least 20 amino acids, more preferably at least 25 amino acids, and most preferably 35 amino acids.
- the length of comparison sequences will generally be at least 50 nucleotides, preferably at least 60 nucleotides, more preferably at least 75 nucleotides, and most preferably 110 nucleotides.
- Sequence similarity can be measured using sequence analysis software (e.g.. Sequence Analysis Software Package of the Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University Avenue, Madison, WI 53705) .
- non- similar positions are preferably, but not necessarily, conservative substitutions for the reference sequence.
- Conservative substitutions typically include substitutions within the following groups: glycine, alanine; valine, isoleucine, leucine; aspartic acid. glutamic acid; asparagine, glutamine; serine, threonine; lysine, arginine; and phenylalanine and tyrosine.
- a particular polypeptide is said to have a specific percent similarity to a reference polypeptide of a defined length, the percent similarity is relative to the reference peptide.
- a peptide that is 50% the same as a reference polypeptide that is 100 amino acids long can be a 50 amino acid polypeptide that is completely identical to a 50 amino acid long portion of the reference polypeptide. It might also be a 100 amino acid long polypeptide which is 50% the same as the reference polypeptide over its entire length.
- a further feature of the invention is a substantially pure antibody that specifically binds FsF- 1.
- antibodies according to the invention may be prepared by a variety of methods.
- the FsF-1 protein, or antigenic fragments thereof can be administered to an animal in order to induce the production of polyclonal antibodies.
- antibodies according to the invention may be monoclonal antibodies.
- Such monoclonal antibodies can be prepared using hybridoma technology (see, e.g., Kohler et al.. Nature 256:495, 1975; Kohler et al., Eur. J. Immunol . 6:511, 1976; Kohler et al.. Bur J. Immunol .
- the invention features antibodies which specifically bind a murine FsF-1 polypeptide, a human FsF-1 polypeptide, or another FsF-1 polypeptide.
- the invention features "neutralizing” antibodies.
- neutralizing antibodies is meant antibodies that interfere with any of the biological activities of FsF-1.
- the activities described herein include stimulation of fibroblast proliferation, stimulation of fibronectin, hyaluronan, and collagen synthesis, and stimulation of chemotaxis.
- the neutralizing antibody may reduce the fibroblast proliferation activity of FsF-1, preferably full length naturally occurring human FsF-1, preferably by 50%, more preferably by 70%, and most preferably by 90% or more. Any standard fibroblast proliferation assay, including the assay described herein, may be used to measure fibroblast proliferation.
- the invention features antibody fragments, including F(ab')2, Fab', Fab, Fv and sFv fragments.
- substantially pure describes a compound, e.g., a protein, polypeptide, or antibody, that is substantially free from the components that naturally accompany it.
- a compound is substantially pure when at least 60%, preferably at least 75%, more preferably at least 90%, and most preferably at least 99%, of the total material (by weight) in a sample is the compound of interest. Purity can be measured by any appropriate method, e.g., in the case of polypeptides by column chromatography, polyacrylamide gel electrophoresis, or HPLC analysis.
- the FsF-1 polypeptide may be used as the active ingredient of therapeutic compositions.
- the active ingredient may be formulated with a physiologically-acceptable carrier or anchored in the membrane of a cell.
- Such therapeutic compositions are used to stimulate fibroblast proliferation and extracellular matrix synthesis, e.g., to promote wound healing.
- the method involves applying the therapeutic composition, preferably topically, to a wound of a mammal in a dosage effective to stimulate fibroblast proliferation and thereby accelerate wound closure.
- the isolated DNA of the invention can be used to detect the level of mRNA encoding FsF-1 in a sample.
- the method involves contacting the sample with all or a portion of a single-stranded nucleic acid of the invention under hybridization conditions which allow the formation of nucleic acid duplexes between the nucleic acid and mRNA in the sample, and then determining the amount of duplexes in the sample as an indication of a propensity for tissue fibrosis.
- the detection of the duplexes can involve any standard techniques for identifying duplex molecules.
- either the nucleic acid of the invention, or the mRNA from the sample are labeled with a chemical moiety which is capable of being detected, including, without limitation, radioactive isotopes, enzymes, luminescent agents, precipitating agents, and dyes.
- a chemical moiety which is capable of being detected, including, without limitation, radioactive isotopes, enzymes, luminescent agents, precipitating agents, and dyes.
- compositions of the present invention can be assembled in a kit for the detection of FsF-1 polypeptides or mRNA.
- kits include reagents containing the nucleic acids or antibodies of the present invention with instructions and suitable packaging for their use as part of an assay for FsF-1.
- the invention features an FsF-1 polypeptide (or a substantially pure preparation thereof) , produced by the expression of a recombinant DNA molecule encoding the FsF-1 polypeptide.
- the polypeptide includes a fragment of a naturally occurring FsF-1 polypeptide.
- the polypeptide may be full length, may contain the 2B3 domain, or subdo ains of 2B3, such as 2B3a and 2B3b, and is capable of stimulating the growth, mitogenesis and chemotaxis of fibroblasts according to the assays described herein. More preferably, the polypeptide also stimulates fibroblast extracellular matrix synthesis.
- the polypeptide includes the amino acid sequence depicted in Fig.
- Another feature of the invention is a therapeutic method designed to mitigate pathological scarring by inhibiting production (via transcriptional or translational mechanisms) of the FsF-1 protein or DNA of the invention.
- the method entails administering to a patient suffering from a chronic inflammatory disease antisense molecules to the DNA of the invention.
- antisense is meant a molecule that is 10 or more nucleotides long and that is the reverse complement of a portion of the coding strand of the double stranded DNA of the invention.
- the invention also features methods for identifying individuals with a propensity for pathological fibrosis.
- the methods include providing a sample from an individual with a chronic inflammatory disease, contacting the sample with an antibody specific for FsF-1 under conditions that permit immunocomplex formation, and detecting an increase in the relative level of the immunocomplex as an indication of a propensity for pathological fibrosis.
- relative level is meant the relative amount of immunocomplex detected when compared to the level in a sample from a normal individual. In an individual at a chronic stage of the disease, an increased level of the immunocomplex in a single sample is indicative that they are at risk of serious fibrosis.
- the method further involves providing a first and a second sample from the individual over a period of time (e.g., every 3 to 6 months over a period of l to 3 years) , and detecting a persistent increase in the relative level of the immunocomplex as an indication of a propensity for pathological fibrosis.
- the sample may be any biological sample.
- the sample is a blood, serum or plasma sample, but may also be a urine sample; a tissue sample (e.g., biopsy); an effusion obtained from a joint, the abdominal cavity (e.g., ascites) , pleural fluid, cerebral spinal fluid, and the aqueous humor; or from the supernatant of cultured peripheral blood mononuclear cells.
- the sample is obtained from a mammal, and even more preferably, the mammal is a human.
- the pathological scarring results from hepatic fibrosis.
- hepatic fibrosis is the result of the disease schistoso iasis.
- the pathological fibrosis is a result of various chronic inflammatory diseases including pulmonary fibrosis, adult respiratory distress syndrome, cystic fibrosis, asthma, emphysema, scleroderma/progressive systemic sclerosis, sarcoidosis, sclerosing cholangitis, primary biliary cirrhosis, glomerulonephritis, renal failure, inflammatory bowel disease, gastrointestinal fibrosis, Crohn's disease, ulcerative colitis, intestinal occlusion, a fibrotic cancer, optic fibrosis, dermal fibrosis, scleroderma, marrow fibrosis, joint fibrosis, and vascular fibrosis sarcoidosis.
- FsF-1 plays an important role in the progression of fibrotic pathogenesis in liver, and tissue fibrosis in other chronic inflammatory disease.
- FsF-1 is overproduced in lymphocytes of the organ wherein scarring develops, and in relatively high amounts (i.e., compared to animals which do not develop fibrosis) in serum, plasma, blood, urine and serous effusions.
- detection of FsF-1 in the lymphocytes from patients with chronic inflammatory diseases using the method of the present invention provides a relatively simple and rapid means to detect those individuals with a propensity to develop the progressive fibrotic forms of these diseases. This provides the advantage of allowing clinicians to limit treatment to only the subpopulation of infected individuals who require antifibrotic and/or anthelminthic therapy.
- Fig. 1 is a gel filtration chromatograph (Biogel P-30) of unconcentrated egg granuloma culture supernatant. Samples of each fraction were assayed at a final concentration of 1/20 for their ability to stimulate fibroblast proliferation (uptake of [ 3 H]- thymidine) . Each point is a mean of three determinations (SEM ⁇ 10% of the mean) . Elution positions of relevant molecular weight standards are indicated. Shown is a representative experiment of more than six experiments.
- Fig. 2 is a heparin-Sepharose affinity chromatograph of a pool of biologically active fractions obtained by gel filtration chromatography (Biogel P-30) of crude granuloma culture supernatant. Thirty 1 ml fractions were collected. Each fraction was tested for its ability to stimulate fibroblast proliferation. The mean cpm of triplicate determinations is indicated (SEM ⁇ 10%) . Shown are the results of a representative experiment of two performed.
- Fig. 3 is a FPLC anion exchange chromatograph of purified FsF-1.
- the eluted material from heparin- Sepharose was applied to a Mono Q column and eluted at a rate of 1 ml/min with a gradient of NaCl (0 to 2.2 M NaCl) .
- SEM ⁇ 10% Shown is a representative experiment of two performed.
- Fig. 4 is a photograph of an SDS-polyacrylamide gel (10% acrylamide; silver stained) .
- FsF-1 (lane 2) was prepared from granuloma culture supernatants by our published methods and used for immunizing rabbits to prepare anti-FsF-1 IgG described in this report.
- the electropherogram of proteins present in unfractionated granuloma supernatant is shown in lane 1. Note that the migration position of FsF-1 (lane 2) corresponds to that of a major protein (MW 60 kD) present in the starting material (lane 1) .
- Fig. 5 is a Western blot of cell-free supernatants from egg granuloma cultures (granuloma supernatant) probed with anti-FsF-1 antibody.
- Granuloma supernatant was subjected to SDS-PAGE, stained with Coomassie Blue (lane a), electrophoretically transferred to Immobilon-P Transfer Membranes (Millipore) and then treated with anti-FsF-1 IgG (lane b) , or pre-immune IgG (lane c) , followed by alkaline phosphatase-conjugated goat anti-rabbit IgG (Promega Corp., Madison, WI) and developed with substrate as described.
- Figs. 6A and 6B are dot blot ELISA of FsF-1 (10 ng) , plasma fibronectin (FN; 20 ng) , acidic fibroblast growth factor (aFGF; 100 ng) , and platelet derived growth factor (PDGF; 40 ng) applied to nitrocellulose paper in a volume of 1 ⁇ l to 5 ⁇ l and then probed with antibodies.
- Figs. 7A and 7B are a pair of graphs.
- 7A depicts a heparin-Sepharose eluate (FsF-l:10 ng/ml) or FGF (5 ng/ml) incubated with either normal rabbit IgG (open bar) or with anti-FsF-1 (closed bar) at a final concentration of 2.5 ⁇ g/ml. Remaining fibroblast-mitogenic activity is represented as percent cpm obtained with untreated mitogens.
- 7B depicts PDGF (10 ng/ml), biologically active peak from P-30 chromatography, or heparin- Sepharose eluate (FsF-1: -10 ng/ml) treated with either normal rabbit IgG (open bar) or anti-PDGF IgG (closed bar; 50 mg/ml) . The supernatants were then tested for fibroblast mitogenic activity. Shown is a representative experiment of three performed.
- Figs. 8A and 8B are graphs showing growth of bovine aortic endotheliai cells (open symbols) and human fibroblasts (solid symbols) in response to FGF (A) or to heparin-Sepharose purified FsF-1 (B) .
- Growth response was determined by counting numbers of cells per culture after a 96 h incubation. Baseline counts (medium alone) were: fibroblasts, 6.5 ⁇ 0.1 x IO 4 ; endotheliai cells, 6.1 ⁇ 0.1 x IO 4 .
- the first two points in B represent responses to FsF-1 at concentrations of 0.01 and 0.1 vol %. Shown is a representative experiment of two performed.
- Figs. 9A and 9B are curvilinear representations of flow cytometry analysis of dissociated granuloma cells stained with NRS plus FITC-conjugated goat anti-rabbit IgG (a) or anti-FsF-1 IgG followed by FITC-conjugated goat anti-rabbit IgG (b) .
- Figs. 10A - 10D are contour plots of flow cytometry analysis of monodispersed cells obtained from isolated hepatic egg granulomas.
- Fig. 11 is an autoradiograph of metabolically- labeled proteins produced by granuloma CD4 + lymphocytes following SDS-PAGE.
- CD4 + lymphocytes were purified by FACS from suspensions of enzymatically-dissociated granuloma cells and incubated for 24 h in the presence of 35 S-methionine- 35 S-cysteine.
- Cell-free supernatants were then either subjected to 10% SDS-PAGE directly (lane 1) or were precleared by incubation with Sepharose- conjugated normal rabbit IgG and then treated with anti-FsF-1 IgG using two different antibody concentration (5 ⁇ g/ml, lane 2; 15 ⁇ g/ml, lane 3) prior to electrophoresis. The migration position of standard molecular weight markers is indicated.
- Fig. 12 is a line graph depicting the results of an ELISA antigen-capture assay of FsF-1 in granuloma supernatants.
- Fig. 13 is a line graph that depicts the levels of FsF-1 in sera of uninfected or infected mice in an ELISA assay.
- Fig. 14A is a line graph that depicts fibroblast [ 3 H]-thymidine incorporation in response to culture supernatants of CDC25 cells stimulated with concanavalin A (con A) for 24 h. Mean ⁇ SEM of triplicate determinations is shown for each concentration of culture supernatant tested.
- Fig 14B is a bar graph that demonstrates the partial neutralization of the fibroblast mitogenic activity in CDC25 culture supernatant. Supernatants were incubated for 1 h with either pre-immune, normal rabbit IgG (NRIgG) , or rabbit anti-FsF-l IgG at 2.5 ⁇ g/ml. The mixture was tested at 5% vol/vol concentration. NRIgG did not affect the response to culture supernatant. Mean ⁇ SEM of triplicate determinations is shown.
- Fig. 15 is a graph that depicts fibroblast [ 3 H]- thymidine incorporation in response to culture supernatants from COS-7 cells transfected with plasmid DNA representing the whole CDC25 cDNA library (closed symbols) and from sham-transfected COS-7 cells (open symbols) . Mean ⁇ SEM of triplicate determinations is shown for each concentration of culture supernatant shown.
- Fig. 16a is a graph that depicts the growth of fibroblasts in response to culture supernatants from COS- 7 cells transfected with plasmid DNA containing the clone 2B3 cDNA insert.
- Fig. 16b is a bar graph that depicts the neutralization of fibroblast stimulating activity in culture supernatants of COS-7 cells transfected with clone 2B3-containing plasmid DNA.
- Fig. 17 is a graph that illustrates sib selection in the cloning of 2B3 cDNA that encodes a fibroblast itogen.
- COS-7 cells were transfected with plasmid DNA and the transfectant supernatants were tested at various concentrations for their ability to stimulate fibroblast [ 3 H] thymidine incorporation.
- pools of clones were sequentially screened and selected for their ability to encode biologically active macromolecules.
- the inverse correlation between the number of clones per screen and the concentration of the corresponding transfectant culture supernatant that maximally stimulated fibroblast responses reflects the progressive enrichment of cDNA that encodes fibrogenic activity.
- Fig. 17 is a graph that illustrates sib selection in the cloning of 2B3 cDNA that encodes a fibroblast itogen.
- Codons 1-25 are derived from the vector; the insert begins with codon AGG (asterisk) and ends with the termination codon TAA (codon 97) .
- Fig. 19 is a bar graph that depicts fibroblast growth in response to 72 h incubation with various doses of the synthetic 2B3 peptide in the absence of serum.
- the mean (+SEM) responses of triplicate determinations in a representative experiment are shown.
- the horizontal line depicts the mean fibroblast number grown in medium alone (baseline) . In all, twelve experiments were performed; cells were enumerated at 72 h in 6 experiments, and at 96 h in 6 experiments. Maximum responses at pM concentrations were 3-4-fold baseline, and 2-3-fold baseline at ⁇ M concentrations.
- Fig. 20 is a graph depicting the fibroblast mitogenic activity of supernatants from cloned T cell hybridomas stimulated with 10 ⁇ g/ml Con A.
- Fig. 21 is a bar graph of the elution profile of the hybridoma-derived mitogen from T hybridoma B12.
- Fig. 22 is a graph depicting the SEA stimulation of FsF-1 production in hybridoma B12.
- Fig. 23 is a photograph of a Western Blot of crude supernatants from con A-stimulated T cell hybridomas using anti-FsFl Mabs.
- Fig. 24 is a bar graph depicting the immunopurification of mitogenic activity with anti-FsF-1 Mab from T hybridoma B12.
- Fig. 25 is the nucleotide sequence of mouse fibrosin cDNA (SEQ ID NO. : 2). Underlined are the PCR primers, T2 and B4.
- Fig. 26 is the nucleotide sequence of human fibrosin cDNA (SEQ ID NO.: 3).
- Fig. 27 is a photograph of a Western blot stained with rat monoclonal antibodies (Mab) . Crude egg granuloma culture supernatants (lane 1) and T cell hybridoma culture supernatants (lane 2) were subjected to SDS-PAGE and electrotransferred to nitrocellulose paper. The presence of fibrosin (60 kD) was revealed by staining with three separate anti-fibrosin Mabs
- Fig. 28 is a graph of fibroblast proliferative responses to fibrosin. Fibrosin was purified by immunoaffinity chromatography from two representative sources: T cell hybridomas (closed circles) and normal mouse serum (closed squares) and applied to fibrobasts in culture. The addition of homologous anti-fibrosin Mab to cultures abrogated the responses to T cell-derived fibrosin (open circles) . Mean ⁇ SEM of triplicate determinations are shown for a representative experiment. Fig.
- FIG. 29 is a bar graph of the results of fibrosin antigen-capture ELISA.
- Wells were coated with rat anti- fibrosin monoclonal IgG-containing hybridoma culture supernatants, the wells were then blocked with gelatin- containing buffer, and 1 pg/ml purified fibrosin was added for 18 h (room temperature) .
- pre- immune rabbit IgG 0.5 ⁇ g/ml
- r ⁇ F IgG 0.5 ⁇ g/ml
- r ⁇ F IgG 0.5 ⁇ g/ml
- r ⁇ F IgG 0.5 ⁇ g/ml
- Fig. 30 is a bar graph of the production of fibronectin by fibroblasts in response to fibrosin and 2B3 synthetic peptide. The graph also shows that these responses are neutralized by anti-fibrosin monoclonal antibody (Mab) .
- Fig. 31A is a graph of fibroblast chemotactic response to purified native murine fibrosin. Mean ⁇ SEM of triplicate determinations.
- Fig. 3IB is a graph of the fibroblast chemotactic response to synthetic 2B3 peptide.
- Fig. 31C is a bar graph of the fibroblast chemotactic response to fibrosin (40 ng/ml) and TGF-,91 (86 pg/ml) and the selective neutralization of the response by anti-fibrosin monoclonal antibody (Mab; 7.5 ng/ml) .
- Figs. 32A - 32D are a series of bar graphs depicting the production of fibronectin by fibroblasts in response to purified native fibrosin after 6 h (open bars) and 24 h (striped bars) of stimulation (panel A) ; the production of hyaluronan by fibroblasts in response to purified native fibrosin (panel B) ; collagen synthesis, as determined by the incorporation of [ 3 H]- proline into collagenase-sensitive protein (panel C; dummy control is a 1.5 M NaCl eluate of a heparin affinity column to which no material had been adsorbed) ; and neutralization of collagen synthesis induction by fibrosin (panel D) .
- fibrosin and TGF-9 were incubated with anti-fibrosin monoclonal antibody and the collagen synthetic response to this mixture was compared to the response of untreated agonists.
- Fig. 33 is a bar graph of spontaneous fibrosin production by smooth muscle cells isolated from the muscularis mucosae of normal human bowel, or bowel from a patient with Crohn's disease.
- Fig. 34 is a bar graph of the concentration of fibrosin (FsF-1; pg/ml) in conditioned medium from cultured rheumatoid synoviocytes that were treated with phytohemaglutin (+PHA) , or were untreated (-PHA) .
- FsF-1 fibrosin
- Fig 35 is a bar graph of the concentration of fibrosin (FsF-1; pg/ml) in sera from Brazilian patients with Schistosomiasis mansoni (Schistosomiasis) , and in sera from normal, non-infected Brazilians (Control) .
- FsF-1 fibrosin
- Fig. 36 is a pair of line graphs depicting the concentration of fibrosin in patients with biliary cirrhosis during the course of treatment with colchicine or ethotrexate.
- Fig. 37 is the nucleotide sequence of human fibrosin cDNA (SEQ ID NO.:11). This sequence includes the sequence that encodes the 2B3 domain.
- Figs. 38A - 38C are a series of photomicrographs of scleroder a cells cultured in MEM Eagle's Medium with 10% FCS and stained with an antibody against type I collagen. The cells were treated with 20 ⁇ g/ml of random IgG (a) , 20 ⁇ g/ml anti-fibrosin antibody (one-day incubation;b) , or 20 ⁇ g/ml anti-fibrosin antibody (two- day incubation;c) .
- Figs. 39A - 39C are a series of photomicrographs of cultured fibroblasts stained with an antibody against type I collagen.
- conditioned medium from normal fibroblasts is added to the cultured cells prior to staining.
- conditioned medium from sclerodermal fibroblasts is added to the cultured cells prior to staining.
- conditioned medium from sclerodermal fibroblasts that has been depleted with anti-fibrosin antibodies is added to the cultured cells prior to staining.
- Figs. 40A - 40C are a series of photomicrographs
- conditioned medium from normal fibroblasts is added to the cultured cells prior to staining.
- conditioned medium from sclerodermal fibroblasts is added to the cultured cells prior to staining.
- conditioned medium from sclerodermal fibroblasts that has been depleted with anti-fibrosin antibodies is added to the cultured cells prior to staining.
- Figs. 41A - 41C are a series of photomicrographs of cultured sclerodermal cells stained with a monoclonal antibody against fibrosin.
- scleroderma cells were treated with 20 ⁇ g/ml random IgG.
- scleroderma cells were treated with 20 ⁇ g/ml anti-fibrosin antibody.
- TGF£ antibodies (type 1, 2, and 3 and 2.5 ⁇ g/ml each, mixed) .
- Fig. 42 is a bar graph depicting the response of fibroblasts to immunopurified human serum fibrosin.
- Fig. 43 is a bar graph depicting the chemotactic response of monocytes to COS cells transfected with a plasmid bearing a 2.8 kb fragment of human fibrosin cDNA
- mice C57BL/6NcrLBr female mice (18 to 20 g; Taconic Farms, Inc. , Germantown, NY) were infected by the intraperitoneal injection of 35-50 cercariae of S. mansoni (Puerto Guatemalan strain) suspended in 0.5 ml sterile saline. The mice were euthanized eight weeks later by inducing C0 2 narcosis and their livers were placed in cold Hanks' buffered salt solution (HBSS) .
- HBSS cold Hanks' buffered salt solution
- livers were homogenized in cold HBSS using a Waring Blender (New Hartford, CT) .
- Granulomas were isolated from hepatic parenchymal debris by three to five cycles of serial sedimentation at 1 x g in HBSS.
- Granulomas were suspended at 10% (v/v) in serum-free culture medium RPMI 1640 supplemented with antibiotics and L-glutamine and cultured for 20 to 24 h at 37°C in an atmosphere containing 5% C0 2 -95% air.
- Cell-free supernatant from the granuloma cultures was retrieved by centrifugation (1000 x g 20 min at 4°C) and filter sterilized (0.22 ⁇ m diameter; Millipore Corporation, Bedford, MA) .
- the supernatants were stored in aliquots at -20 or -70 ⁇ C.
- cell-free supernatants were retrieved by centrifugation (200 g x 10 min) and used to purify FsF-1 for immunization of rabbits, or to conduct Western blot analysis.
- granuloma cells were dissociated by collagenase treatment using methods as described in Wyler et al. , J, IimJH D l ⁇ 132:3142 (1984). The granuloma cell suspension was first washed with HBSS and then with a solution of phosphate- buffered 0.15 M NaCl containing NaN 3 (0.015 M) and goat serum (1% v/v; Sigma Chemical Co., St. Louis, MO).
- the washed cells were pelleted and incubated at 4°C for 0.5 h each in the presence of 10-15 ⁇ g/ml of normal rabbit IgG or of rabbit anti-FsF-1 IgG, washed, and then treated with 10 ⁇ g/ml goat anti-rabbit IgG (H and L chain specific) antibody conjugated with fluorescein isothiocyanate (FITC; Fisher Scientific, Pittsburgh, PA) .
- FITC fluorescein isothiocyanate
- unstained or FITC-stained cells were treated with phycoerythrin-conjugated rat anti-mouse CD4 antibody (5 ⁇ g/ml; Becton-Dickinson, Mountain View, CA) .
- Antibody-treated cells were sorted by FACStar Plus flow cytometry and analyzed by a FACScan (Becton- Dickinson) or a Coulter Epics 541 flow cytometer (Coulter Electronics Inc., Hialeah, FL) . The fields were gated to exclude autofluorescent and dead cells.
- the CD4 + sorted cells were washed and suspended (0.6-1.0 x 10 6 /ml) in serum-free medium RPMI 1640 supplemented with 0.3 mg/ml bovine serum albumin (BSA; Sigma, St. Louis, MO) and incubated for 24 h at 30°C in 5% C0 2 -95% air humid atmosphere. Cell-free supernatants were retrieved by centrifugation (200 g x 10 min; 4°C) and analyzed for fibroblast mitogenic activity.
- BSA bovine serum albumin
- cells were suspended in serum-containing supplemented medium at a density of 5 to 6 x l0 /ml.
- One ml of the cell suspension was seeded in each well of a 24-well polystyrene tissue culture plate (Nuncalon) and incubated overnight. Cells were then washed twice with warm (37°C) HBSS and replenished with serum-free medium. On the next day, 100 ⁇ l test samples were added to each well. Twenty hours later, 1 ⁇ Ci[ 3 H]-thymidine (specific activity 6.7 Ci/mM, Dupont- NEN Research Products, Boston, MA) was added to each well for 4 h.
- cell growth was also assessed by direct quantitation.
- the cells were cultured as described above. Test samples were added for 96 h, after which the cultures were washed and detached from the onolayer by treatment with trypsin-EDTA.
- Monodispersed cells were counted in a hemocytometer chamber (Cambridge Instruments, Inc., Buffalo, NY).
- a "batch elution" procedure was used for preparing biologically active material from heparin- Sepharose beads.
- the biologically active fractions prepared by initial gel filtration chromatography were adsorbed to heparin-Sepharose as described above.
- the tubes were centrifuged (1000 x g for 10 min) and the supernatant was recovered and filter-sterilized (0.22 ⁇ m diameter pore) .
- the beads were then washed three times with PBS. After the last wash the beads, suspended in an equal volume of 3.0 M NaCl, were gently mixed at 37°C for 1 h.
- the supernatant was removed by centrifugation and dialyzed before testing in the biologic assays.
- the heparin-Sepharose purified material was designated FsF-1.
- FPLC A ion Exchange Chromatographv The fractions eluting from heparin Sepharose with 1.5 M NaCl were dialyzed (6 to 8 kDa cutoff) at 4°C against two to three changes of PBS, followed by two changes of 20 mM Tris-HCl, pH 8.0, and applied to a Mono Q column (HR 5/5, Pharmacia, Uppsala, Sweden) that had been equilibrated in the starting buffer (20 mM Tris-HCl, pH 8.0).
- the fast-performance liquid chromatography apparatus (Pharmacia) was operated at 4°C. Elution was achieved with a gradient of 0 to 2.2 M NaCl in 20 mM Tris-HCl, pH 8.0, at a flow rate of 1 ml/min. Forty 1 ml fractions were collected. Absorbance (280 nm) and the conductance of each fraction was monitored and 0.3 mg/ml of BSA was added as a carrier protein before each fraction was dialyzed against medium and tested in the proliferation assays. SDS-PAGE
- Samples were combined with an equal volume of buffer consisting of 10 mM Tris-HCl, pH 6.8, 2% SDS, 5% glycerol, 2% dithiothreitol, and 0.01% bromophenol blue. Samples were analyzed by SDS-PAGE as described by Laemmli (Laemmli et al.. Nature 227:680 (1970)). Separating gels of 10% acrylamide and stacking gels of 7% were used. Gels were stained with silver nitrate (Morrissey, Anal. Biochem.. 117:307 (1981)).
- the concentrate was emulsified in an equal volume of CFA (Sigma) .
- the rabbits were boosted at 4- to 6-wk intervals by intradermal injections of the same amount of purified FsF-1 in incomplete Freund's adjuvant (IFA) (Sigma) .
- IFA incomplete Freund's adjuvant
- IgG from preimmune or immune serum was prepared by protein A-Sepharose (Sigma) chromatography (Goding, J. Immunol. Methods 20:241 (1978)) .
- the specificity of the anti-FsF-1 antibody was assessed by dot-blot ELISA as described in Hawkes et al. , Anal. Biochem. 119:142 (1981). Briefly, purified FsF-1 (10 to 15 ng) ; purified acidic FGF (100 ng, 200 ng) ; PDGF (40 ng, 100 ng) ; purified human plasma fibronectin (2, 20, 100 ng (prepared as described in Wyler et al., J. IfflPMn?”
- rhIL-2 (2 ng, 12 ng, 20 ng; Genzyme, Boston, MA); rmIL-3 (2.5 ng, 7.5 ng; Genzyme) rmIL-4 (0.7 ng, 4 ng, 7 ng; Collaborative Research, Bedford, MA); rmIL-6 (2.5 ng, 15 ng, 25 ng; Biosource International, Westlake Village, CA) ; rh IL-7 (0.75 ng, 4.5 ng, 7.5 ng; Biosource International); and rm GM-CSF (0.25 ng, 1.5 ng; 2.5 ng; Genzyme), were adsorbed to nitrocellulose paper (Bio-Rad) in a volume of 1 to 5 ⁇ l.
- Bio-Rad nitrocellulose paper
- the nitrocellulose was then washed overnight in blocking buffer (PBS containing 5% w/v Carnation nonfat powdered milk) .
- the nitrocellulose was then incubated at room temperature for 1 h with anti-FsF-1 IgG antibody (1:50 final dilution) .
- After extensive washing with blocking buffer the nitrocellulose was incubated for 0.5 to l h at room temperature in alkaline phosphatase-conjugated goat anti-rabbit IgG (Promega Corporation Madison, WI) .
- the development of the blot was carried out by incubation with substrate (containing nitroblue tetrazolium chloride and 5-bromo-4 chloro-3imodyl phosphate, p-toluidine salt (Promega)) dissolved in alkaline phosphatase buffer (100 mM Tris-HCl, 100 mM NaCl, 5 mM MgCl 2 , pH 9.5): 33 ml nitroblue tetrazolium chloride and 16.5 ml 5-bromo-4 chloro-3-imodyl phosphate p-toluidine salt were used for every 5 ml of the buffer. The reaction was stopped with deionized water.
- substrate containing nitroblue tetrazolium chloride and 5-bromo-4 chloro-3imodyl phosphate, p-toluidine salt (Promega)
- alkaline phosphatase buffer 100 mM Tris-HCl, 100 mM NaCl, 5 mM
- the samples were incubated with immobilized protein A- Sepharose to remove Ag-antibody complexes; the samples were centrifuged at 1000 x g for 10 min and the supernatant was tested for fibrogenic activity.
- Amino acid composition of FsF-1 was determined by analysis of the 1.5 M NaCl eluate from the heparin- Sepharose bound to polyvinylidene difluoride membrane (Millipore Corp., Bedford, MA (LeGendre et al., Biotechniques 6:154 (1988)). The amino acid composition was determined by the standard method of Waters PICO-TAG. Interleukins Murine rIL-3, IL-4, and recombinant mouse granulocyte-macrophage CSF were obtained from Genzyme, Boston, MA. Murine rIL-6, human rIL-7, and human rIL-8 were obtained from Bio-Source International, Westlake Village, CA.
- Human PDGF, a-endothelial cell growth factor, and goat anti-human PDGF (IgG) were purchased from Collaborative Research.
- Bovine acidic FGF used for the dot blot ELISA assay and neutralization studies and rabbit anti-bovine acidic FGF fragment (Leu 60-Leu 98) , polyclonal IgG were obtained from UBI, Lake Placid, NY.
- Biosynthetic Labeling of FsF-1 CD4 + cells from granulomas were cultured for 24 h in methionine and cysteine-free RPMI 1640 medium (Select mine»Kit, GIBCO, Grand Island, NY) to which was added 75 ⁇ Ci Tran 35 S-Label» ( 35 s E.
- coli hydrolysate labeling reagent containing 70% L-methionine [ 35 S] and 15% L-cysteine [ 35 S]; sp. act. 1181 Ci/mmole; ICN Biomedical, Irvine, CA) .
- the cell-free culture supernatants were collected at 24 h by centrifugation (200 g x 10 min) and 200 ⁇ l of the supernatant was first incubated (1-2 hr; 4°C) with normal rabbit IgG (NRIgG; 5 or 15 ⁇ g in 200 ⁇ l) and the mixture was then incubated (1 hr; 4°C) with protein A-Sepharose (50-100 ⁇ l; Sigma) .
- Heparin-Sepharose fractionated material was subjected to anion-exchange FPLC chromatography (Fig. 3) .
- Fibroblast mitogenic activity eluted from the column with 1.2 to 1.5 M NaCl in a single active peak; maximum activity was present in fractions eluting with 1.5 M NaCl. These fractions were active at a concentration of 1/100 to 1/1000. Only fractions 17 and 18 detectably adsorbed uv light (280 nm) .
- Commercial heparin from porcine intestinal mucosa, Sigma, cat. no. H-3125
- when applied to a mono Q column under the same conditions also eluted in these two factors.
- the biologically active fraction that eluted from heparin-Sepharose was analyzed by silver stain of SDS- PAGE (Fig. 4) and under reducing conditions revealed a single band with molecular mass - 60 kDa. This band corresponds to the migration position of one of the major proteins detected in electropherograms of crude granuloma supernatant.
- the heparin affinity of FsF-1 suggested that the mitogen might be the same as a previously-defined HBGF. Such factors are classified in part according to their anodic or cathodic migratory behavior during IEF (Lobb et al., J. Biol. Chem. 261:1924 (1986)).
- the granuloma-derived mitogen has pi-6.2 (Wyler et al., J. IlfflftV ⁇ Pl T 129:1706 (1982)), thus FsF-1 has a characteristic of class l (acidic) HBGF.
- Anti-FsF-1 antibody detected FsF-1 in both purified form and in crude granuloma supernatant in a dot-blot ELISA assay (Fig. 6) .
- the antibody did not detect acidic FGF or PDGF, mitogens that were detected with the appropriate homologous antibodies.
- anti-FsF-l did not detect plasma fibronectin or acidic FGF in a dot-blot ELISA; nor did anti-fibronectin antibody react with FsF-1.
- Crude granuloma supernatant had no biological activity characteristic of TNF in an L929 cytotoxicity assay and purified TNF was not mitogenic in our assay which utilizes serum-free conditions.
- HBGF HBGF-like growth factor-1
- fibroblasts and endotheliai cells proliferate in response to acidic FGF. Inasmuch as the magnitude of the response of endotheliai cells to the lower ( ⁇ 2 ng/ml) concentration of acidic FGF is greater than that of fibroblasts, these cells appear to be the more sensitive to this mitogen.
- FsF-1 in concentrations in the range of 1 to 40 ng/ml did not induce endotheliai cell proliferation (Fig. 8B) .
- cytokines rIL-3 (0.2-200 U/ml) , rIL-4 (0.05-20 U/ml) rhIL-5 (1-1000 U/ml) , rIL-6 (0.002-100 U/ml), IL-7 (0.02-100 U/ml) rIL-8 (0.02-100 U/ml) or GM-CSF (0.3-20 U/ml).
- the lack of relevant biological activity in these cytokines implies that FsF-1 is unique.
- Fibroblast proliferate response ( 3 H-thymidine incorporation) to cluture supernatants of CD4 + lymphocytes from schistosomal egg granulomas Additive to 3 H-thymidine fifrrPblagt gu t ⁇ rg incorporation rcPMi 1
- Heparin affinity chromatography has proven to be a valuable purification procedure in the isolation of certain mesenchymal growth factors and angiogenic factors (Lobb et al., supra) .
- An advantage of this technique is that the relatively high affinity binding of these factors to heparin is uncharacteristic of most proteins (Lobb et al., supra) .
- the simplicity of the scheme we were able to devise for purifying FsF-1 from culture supernatants is a consequence of its heparin-binding property.
- FsF-1 is heparin- binding
- the granuloma-derived mitogen is a protein with pi -6.2.
- FsF-1 might be a member of the acidic heparin-binding growth factor class of proteins (class 1 HBGF) , mitogenic proteins of diverse cellular origin that are structurally the same or closely related, and highly conserved between mammalian species (Harper et al., Biochemistry 25:4097 (1986)).
- the class 1 HBGF exemplified by acidic FGF, are all potent mitogens for fibroblasts as well as endotheliai cells.
- FsF-1 probably is distinct from FGF and sensu stricto is not a class l HBGF. Supporting this conclusion are our observations that antibodies prepared against FsF-1 neither react with FGF in a dot-blot ELISA nor neutralize its biologic activity, whereas they do both to FsF-1 (Figs. 6 and 7). Finally, the amino acid content of FsF- 1 and FGF (acidic and basic) reveal differences indicating that these molecules are not the same (Table 1) , and the amino acid sequence of the peptide derived from FsF-1 is distinct from other known proteins.
- the antibody preparations permitted us to distinguish FsF-1 from other heparin-binding growth factors (Prakash et al., supra ) and to determine by flow cytometry that a subpopulation (20-25%) of CD4 + lymphocytes in granuloma cell suspensions apparently express FsF-1 on their surface (Figs. 9 and 10) .
- fibroblast mitogenic activity can be detected in extracts of recently isolated egg granulomas (Wyler et al., J. Infect. Pis. 144:254 (1981)) and is detectable in the cell-free supernatants of isolated egg granulomas within a few hours of their in vitro incubation (Wyler et al., supra) .
- unfractionated splenocytes and splenic CD4 + lymphocytes isolated by flow cytometry fail to spontaneously secrete fibroblast mitogens (Wyler et al.. Infect. lTHfflu.ni 38:103 (1982); and the present study).
- sensitized splenic lymphocytes stimulated with an aqueous extract of schistosomal eggs (concanavalin-binding fraction of soluble egg antigen) do secrete a fibroblast mitogen, presumably FsF-1 (Wyler et al., filiEEfl).
- FsF-1 detected by immunoprecipitation corresponded to a prominent 60 kDa protein produced by isolated granuloma CD4 + lymphocytes (Fig. 5) .
- Our results suggest that FsF-1 might be a major protein produced by this subpopulation of granuloma cells.
- sensitized splenic lymphocytes from S. mansoni-infected mice when stimulated with an aqueous extract of schistosoma eggs secrete a fibroblast mitogen, presumably FsF-1 (Wyler et al., Infect. ⁇ n ⁇ n. 38:103 (1982)).
- CD4 + cells are stimulated in vivo to produce FsF-1 in response to egg antigens. Based on our current observation, such production may continue at least briefly when the lymphocytes are dissociated from the eggs and antigen-presenting cells.
- FsF-1 not only is secreted but also can remain associated with the surface of CD4 + lymphocytes suggests that in addition to the action of the secreted cytokine, direct contact between membrane-associated FsF-1 positive lymphocytes and fibroblasts might stimulate fibroblast growth.
- cytokines IL-1, TNF, TGF3
- IL-1, TNF, TGF3 cytokines
- fibroblast growth factors some of which were purified from other sources and were recognized for this biological property (PDGF [Ross et al., ____! 46:155 (1986)], FGF [Gospodarowicz et al., J. Biol. Chem. 250:2515 (1975); Gospodarowicz et al., J. BiaL,.253:3736 (1978)]), and heparin-binding epidermal growth factor [HB-EGF Higashiyama et al.. Science 251:936 (1991)]) have been found to be produced by macrophages.
- PDGF Ross et al., _____! 46:155 (1986)
- FGF Gospodarowicz et al., J. Biol. Chem. 250:2515 (1975); Gospodarowicz et al., J. BiaL,.253:3736 (1978)]
- FsF-1 is distinct from these fibroblast growth factors.
- the fact that FsF-1 is a lymphokine is an additional distinguishing characteristic. Indeed, because we have not detected fibroblast mitogenic activity in several purified and recombinant lymphokines, and since avid heparin-binding is not a known characteristic of most lymphokines, we believe that FsF-1 is a previously unidentified lymphokine. DETECTION OF FsF-1 IN GRANULOMA SUPERNATANTS AND
- FsF-1 can be detected in highly-dilute granuloma supernatant in an antigen-capture ELISA (Nourel, et al.
- the assay apparently is sensitive to at least pg/ml concentrations, consistent with expectations based on similar antigen-capture assays for other lymphokines (Fig. 12) .
- An antigen-capture ELISA was also used to detect FsF-1 in sera of uninfected C57BL/6 mice or mice infected with Schistosoma mansoni for 8 or 20 weeks. Sera from two sets of mice were compared simultaneously in the same assay.
- IgG Antibody Neutralization of Fibrogenic Activity
- polyclonal IgG was prepared by immunizing rabbits with highly purified murine FsF-1, as previously described. This antibody preparation did not react (by dot blot ELISA) with a variety of recombinant murine lymphokines. IgG purified from pooled sera of rabbits prior to immunization (NRIgG) , and which did not react with FsF-1, served as a control.
- Cell-free supernatants (undiluted) from lymphocytes or transfected COS-7 cells were incubated with IgG (final concentration, 2.5 to 7.5 ⁇ g/100 ⁇ l) at 37 ⁇ C for 2-3 h in polypropylene culture tubes (Falcon #2063; Becton-Pickinson Labware, Lincoln Park, NJ) that had been previously treated with BSA (1 mg/ml) and washed, to reduce non-specific adsorption of proteins. Immune complexes were removed from selected mixtures with protein A coupled to Sepharose beads (Sigma).
- the beads were removed by centrifugation (lOOOg x 10 min.) The samples were then filter-sterilized (0.22 ⁇ m diameter pore size; Millipore Corp. , Bedford, MA) and tested in a fibroblast proliferation assay.
- CD4 + lymphocyte clones and cell lines were screened for their ability to secrete fibroblast mitogenic activity into culture supernatants following in vitro stimulation.
- Cells were propagated in supplemented medium RPMI 1640 containing 10% FBS.
- Cells at mid-log growth were washed extensively in HBSS and IO 6 cells were cultured in 1 ml serum-free medium supplemented with 0.3 mg/ml BSA and 10 ⁇ g/ml concanavalin A (Con A; Sigma Chemical Co.,St.
- a murine cDNA library prepared from mRNA isolated from Con A-stimulated cells of the CDC25 line was obtained from DNAX Research Institute of Molecular and Cellular Biology, Palo Alto, CA.
- the library was constructed in the vector pcDSR ⁇ 296 which contains a unique promoter that permits high-level, transient expression of the cDNA insert in COS-7 cells (Takebe et al., Mol. Cell Bio. 8:466-472, 1988).
- pcDRa296 allows a high level of expression of full-length cDNA inserts under the control of the simian virus 40 (SV40) early promoter.
- SV40-derived DNA fragments are arrayed in these vectors to permit transcription, splicing, and polyadenylation of the cloned cDNA.
- a DNA fragment containing both the SV40 early region promoter and two introns normally used to splice the virus 16s and 19s late mRNAs is placed upstream of the cDNA cloning site to ensure transcription and splicing of the cDNA transcripts.
- This DNA fragment can promote two alternate kinds of splicing. Most often (60-70% of transcripts) splicing occurs at the 16s RNA intron junction and places the cDNA initiator ATG codon first in line from the 5' end of the mRNA.
- E.coli transformants containing the pcDSR ⁇ 296 vectors were expanded in L-broth medium containing ampicillin (50 ⁇ g/ml) and plasmids were isolated on Qiagen columns (Qiagen Inc., Chatsworth, CA) . For transfection, 5 x 10 5 COS-7 cells (Okayama et al. Meth. Enzvm.
- 154:3-28, 1987 were seeded on 60 mm tissue culture dishes (Falcon) in supplemented Dulbecco's modified Eagle's medium (DMEM; GIBCO) containing 10% FBS (GIBCO) .
- DMEM Dulbecco's modified Eagle's medium
- FBS FBS
- Cells were grown overnight to a density visually estimated to be 60-70% confluency.
- Cells were then washed with serum-free DMEM buffered with 5 mM Tris (pH 7.4) and plasmid DNA (1-5 ⁇ g) in serum-free medium (4 ml per plate) was added, followed by the addition of DEAE dextran (200 ⁇ g/ml; Pharmacia, Piscataway, NJ) .
- COS-7 cells were washed and treated for 2-3 h with 100 ⁇ M chloroquine (Sigma) in the presence of 2% FBS. Cells were then washed and grown overnight in DMEM with 4% FBS. The following day, cells were washed and replenished with DMEM containing 0.3 mg/ml BSA. Forty-eight to seventy-two hours later, culture supernatants were collected and tested for their ability to stimulate fibroblast proliferation.
- COS-7 cells were transfected with the pcDSR ⁇ 296 plasmid containing a murine IL-4 cDNA insert (DNAX) , and were subsequently maintained under the above conditions except that the cells were cultured in 2% FBS. Supernatants of these cultures were harvested after 48 to 72 hours and tested for IL-4 activity on an indicator cell line (HT-2; Rennick et al. J. Immunol. 134:910-914, 1985) and in the fibroblast proliferation assay.
- DNAX murine IL-4 cDNA insert
- Nucleotide sequences on both positive and negative cDNA strands were determined by the dideoxy-chain termination protocol with supercoiled DNA templates (Sanger et al., Proc. Natl. Acad. Sci. USA 74:5463-5467, 1977) . Areas which were rich with G-C residues were sequenced by PCR using a cycle sequencing kit from Epicentre Technologies. The nucleotide sequence was compared by FASTA and BLAST programs to sequences archived in GenBank.
- CDC25 Lvmphocvte Line Produces Fibroblast Mitogen Of the 30 lymphocyte lines and T cell hybridomas we tested, five elaborated detectable fibroblast mitogenic activity in culture supernatants following in vitro stimulation with Con A for 24 h. Con A had no intrinsic fibroblast mitogenic activity in our fibroblast assay.
- line CDC25 a Th2 line for which a cDNA library was available for further analysis. Culture supernatants of CDC25 cells stimulated fibroblast [ 3 H]- thymidine incorporation in a concentration-dependent manner; peak responses were detected at a concentration of 10% (the maximum tested; Fig. 14A) .
- Anti-FsF-1 IgG reduced the activity of the CDC25 culture supernatant by 21% and 47% with 2.5 ⁇ g/100 ⁇ l and 5 ⁇ g/ ⁇ l IgG respectively (Fig. 14B) , relative to responses in the presence of the same concentrations of pre-immune IgG (NRIgG) which we previously established does not significantly alter the fibroblast responses to purified FsF-1. Furthermore, in Western blot anti-FsF-1 IgG recognizes a single protein band (apparent MW 50-60 kD) in CDC25 culture supernatants subjected to SDS-PAGE; NRIgG does not recognize this protein.
- CDC25 Library Contains cDNA that Encodes a rifrrpfrlapt grpwth Fact-pr
- the CDC25 library was partitioned into pools of IO 3 clones that were seeded into separate wells of microtiter plates containing L-broth and ampicillin. Pools, estimated to contain IO 4 clones, were prepared by combining wells within a row. C0S-7 cells were transfected with plasmid DNA prepared from these pools and the transfectant culture supernatants (tested at various concentrations, to a maximum of 10%) were assayed for their ability to enhance fibroblast [ 3 H]-thymidine uptake at least 2-3 fold above background (positive transfectant) .
- pool B was selected because the biological activity in the supernatant of pool B transfectants could be neutralized with anti-FsF-1 IgG.
- Pool B was subdivided into 8 separate pools (each containing approximately IO 3 clones) and plasmid DNA prepared from each pool was used to transfect COS-7 cells. Conditioned medium from four of the transfectants (50%) had significant mitogenic activity. Based on antibody neutralization of bioactivity, one of the pools (2B) was selected. Pool 2B was then subdivided into 16 pools, each estimated to contain 100 clones. Five of the pools (31%) produced positive transfectants.
- Clone 2B3 contains a cDNA insert of 216 bp and a single open reading frame (ORF) starting with arginine (nucleotide position 76-78; Fig. 18; SEQ ID NO.: 1) and terminating with leucine (nucleotide position 289-291) followed by the stop codon TAA.
- ORF codes 71 amino acids and is followed by 11 untranslated codons that precede the poly(A) tail.
- Fibroblast Growth Stimulation bv Synthetic Peptide A 71-mer peptide which was synthesized from the deduced amino acid sequence of 2B3 stimulated fibroblast proliferation (based on cell counting) in a concentration-dependent manner (Fig. 19) .
- peak mitogenic activity was observed with peptide concentrations between IO" 13 and 10" 11 M; additional activity was detected at concentrations in the 10 ⁇ 6 M range.
- the dose-response pattern we observed is reminiscent of our experience with crude and purified natural FsF-1 as well as with supernatants of the 2B3 transfectant (Figs. 16A-B) .
- T-hybridoma cells that secrete FsF-1 upon Con A stimulation because this relatively homogeneous source: (1) provides a "renewable" in vitro source from which we can purify natural FsF-1, (2) provided mRNA from which full length fibrosin cDNA could be prepared for analysis and heterologous expression and, (3) allows standardization of in situ hybridization methods to detect fibrosin mRNA, and in the future can be used to study regulation of fibrosin gene expression.
- FsF-l + lymphocytes were selected by FACS (using rabbit anti-FsF-1 IgG and FITC- goat anti- rabbit IgG as described previously) from a population of splenocytes obtained from a mouse with 8 week S. mansoni infection and stimulated overnight with Con A. Individual cells were fused with thymoma BW 5147 cells using standard methods (Coligan et al., eds.. Current Protocols in Immunology, Vol. 1, John Wiley & Sons, Inc., pp. 3.14.1-3.14.11 (1994)).
- hybridomas that on stimulation with Con A (in the absence of serum) produced fibroblast mitogenic activity, and confirmed by ELISA, neutralization, and immunopurification that this biological activity derived from FsF-1 in the supernatants. Positive hybridomas were subcloned 2-3 times by limiting dilution. Cloned hybridoma cells were adapted to growth in GIBCO SFM (serum-free medium) to avoid serum contamination of culture supernatants. Representative results are shown in Fig. 20. Analysis of these T cell hybridomas indicate T hybridomas produce fibroblast mitogenic activity (Fig. 20) .
- the hybridoma-derived mitogen is heparin-binding and elutes with high NaCl concentration (two characteristic properties of granuloma-derived FsF- 1) (Fig. 21) : the non-binding fraction (fall-through) had no activity, and the 1.0 and 1.5 M NaCl eluate contained only 60 kD protein (SDS-PAGE) that was detected by Western blot using anti-FsF-1 antibodies.
- SEA (10 ⁇ g/ml; fraction that lacks direct mitogenic activity) stimulates hybridoma ⁇ B12 production of FsF-1. Response to various concentrations of cell culture supernatant are shown relative to CPM in fibroblasts grown in medium alone in Fig. 22.
- the control was identical treatment of T-hybridoma supernatant, but excluding incubation with anti-FsF-1 Mab. Bioactivity was compared with heparin- purified T-hybridoma-derived mitogen.
- Medium control is CPM in fibroblast cultured with medium alone. (Fig. 24).
- T-hybridomas produce the same FsF-1 that we previously purified from granuloma supernatants.
- Tl C-TCA-CTA-AGC-CAG-AGG-CCA-AAG-TG (SEQ ID NO.
- Bl A-CCA-GGA-AGG-GAA-TTA-TAG-GGA-GG (SEQ ID NO. : 6)
- B2 CC-TTT-AGT-TCC-TCC-TTC-CTC-AGC-C (SEQ ID NO. : 7)
- B3 CA-TGA-GAA-CTT-GGG-TGG-TAG-GCG-A (SEQ ID NO. : 8)
- PCR primers T1/B3, T1/B2, and Tl/Bl
- total RNA prepared from mouse T-hybridoma cells we obtained RT PCR products with the expected sizes of 60 bp, 93 bp, and 194 bp, respectively.
- PBMC peripheral blood mononuclear cells
- RACE PCR Frohman, in PCJR Protocol . A guide to methods and applications, p. 28- 38. Academic Press, NY 1990
- RACE NO MORE PCR Weis, Nucleic Acid Res. 22:3427-3428, 1994
- RACE NO MORE was successful with mouse cDNA, we pursued this method.
- RACE NO MORE method is based on the rare event of 5' end PCR priming in a linear PCR with only one reverse primer annealed to a random hexamer primed cDNA whose 5' end sequence is unknown.
- a subsequent second PCR with the first primer and a second reverse primer located 5' end to the first primer specifically amplifies the 5' end unknown region plus a stretch of known sequence at the 3' end.
- the 470 bp and 435 bp products were then cloned into pCR3 vector of Invitrogen's Eukaryotic TA Cloning Kit following the manufacturer's protocol. DNA sequencing of several resulting plasmid clones of each product revealed that the 470 bp and 435 bp products all contained the expected portions of mouse 2B3 sequence at the 3' end. The 5' end was composed of the Bl sequence, followed by a 9 bp portion of the 2B3 segment (an artifact—not unexpected— created by this new PCR approach) , which in turn was followed downstream by a new 311 bp sequence adjacent to the complete 2B3 sequence.
- the 311 bp sequence contained three in-frame ATG triplets; the first one was located at bp 76, the second 15 bp downstream from the first.
- the sequences surrounding the first and the second ATGs conform with Kozak's criteria for translation initiation (Kozak, J. Cell Biol. 108:229-241, 1989), and thus, could be sites for translational initiation.
- the mouse cDNA has a total length of 571 bp with a 75 bp untranslated leader sequence and encodes a polypeptide chain of about 149 residues (including 78 encoded by the upstream 311 bp sequence and 71 encoded by 2B3) (Fig. 25; SEQ ID NO.: 2).
- Primer T2 is a 28-mer forward primer derived from the mouse sequence in the 5' end untranslated leader sequence, upstream from the first ATG; primer B4 is a 35-mer reverse primer, derived from the mouse 2B3 sequence at its 3' end untranslated region, including 10 A's of its poly-A tail of more than 50 A's.
- T2 AAG-CCA-GGG-TTG-GAA-GGC-AAA-GGT-CAC-A
- Both PCR products were gel purified, and then used as templates in separate PCRs with a panel of seven pairs of mouse primers: T2/B1, T2/B2, T2/B3, Tl/Bl, T1/B2, T1/B3, and T1/B4.
- the mouse 524 bp PCR product generated seven bands of the expected sizes, and the human 500 bp PCR product yielded six bands of the expected sized.
- DNA sequencing of both PCR products have demonstrated that human (Fig. 26; SEQ ID NO. : 3) and mouse (Fig. 25; SEQ ID NO. : 2) fibrosin cDNAs are comprised of two portions: (1) the 311 bp segment in the 5' region; and, (2) the 2B3 segment in the 3' region.
- Polypeptides according to the invention can be produced by expression from a recombinant nucleic acid having a sequence encoding part or all of an FsF-1 polypeptide of the invention, using any appropriate expression system: e.g., transformation of a suitable host cell (either prokaryotic or eukaryotic) with the recombinant nucleic acid in a suitable expression vector.
- a suitable host cell either prokaryotic or eukaryotic
- the precise host cell used is not critical to the invention.
- the method of transfection and the choice of expression vector will depend on the host system selected. Mammalian cell transfection methods are described, e.g., in Ausubel et al.
- Stably transfected cells can be produced by integration of FsF-1 DNA into host cell chromosomes.
- DNA sequences encoding the polypeptides of the invention can also be expressed in a prokaryotic host cell.
- DNA encoding an FsF-1 polypeptide of the invention or a fragment thereof is carried on a vector operably linked to control signals capable of effecting expression in the prokaryotic host.
- the coding sequence can contain, at its 5' end, a sequence encoding any of the known signal sequences capable of effecting secretion of the expressed protein into the periplasmic space of the host cell, thereby facilitating recovery of the protein and subsequent purification.
- Prokaryotes most frequently used are various strains E. coli j however, other microbials can also be used.
- Plasmid vectors are used which contain replication origins, selectable markers, and control sequences derived from a species compatible with the microbial host.
- Commonly used prokaryotic control sequences are defined herein to include promoters for transcription initiation, optionally with an operator, along with ribosome binding site sequences.
- fibrosin production appears to be a risk factor for the development of pipe-stem fibrosis.
- fibrosin from two sources of serum- free conditioned medium: (1) egg granulomas and (2) cloned T cell hybridomas stimulated with concanavalin A (Con A) .
- egg granulomas were isolated from the livers of mice infected for 8 weeks with S. mansoni and incubated overnight in medium RPMI 1640.
- T cell hybridomas were prepared by published methods (Kruisbeck et al., Current Protocols in vol. I. New York, John Wiley & Sons, Inc. (1994)).
- T cell hybridomas were initially selected in HAT medium (GIBCO/BRL
- fibrosin was confirmed by the ability of conditioned media of Con A-stimulated cloned hybridomas to stimulate human fibroblast proliferation (Prakash et al., J. Immunol. 61:3985-3987 (1993)), and the ability of rabbit anti-fibrosin IgG to specifically neutralize this biological activity (reduction of response >50%) .
- Fibrosin was purified from the two sources by a slight modification of published methods (Prakash et al., J. Immunol. 146:1679-1684 (1991)). Conditioned media were first subjected to affinity chromatography on immobilized gelatin to remove fibronectin (Engvall et al., Int. J. Cancer 20:1-5 (1977)). Nonadsorbed material (fall-through fraction) was then subjected to heparin- affinity chromatography (HiTrap" Heparin; Pharmacia Biotech, Piscataway, NJ) as described (Prakash et al., _ ⁇ _. Immunol. supra) .
- the loaded column was first washed with 0.5 M NaCl and then the 1.5 M NaCl eluate was collected.
- This fraction contains a single detectable protein (60 kD) when it is subjected to sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS-PAGE) under reducing conditions (Prakash et al., J. Immunol.
- Monoclonal antibodies to murine fibrosin were produced by B cell hybridomas that were prepared by fusing rat splenocytes with myeloma line SP2/0-Agl4 (TIB# 1581, originally obtained from ATCC; Yokoyama, Current Protocols in Immunology, vol. I. New York, John Wiley & Sons, Inc. (1994)).
- Female Lewis rats received a primary immunization by intraperitoneal (ip) injection of heparin-purified fibrosin (from granuloma-conditioned medium; 2 ⁇ g protein in Freund's complete adjuvant) , followed by six ip booster injections of fibrosin (2 ⁇ g protein in Freund's incomplete adjuvant) at 2-week intervals.
- IgG was purified from serum-free hybridoma conditioned medium (Hybridoma SFM; cat.# 125045; GIBCO/BRL) by immunoaffinity chromatography with immobilized mouse anti-rat K (MAR) monoclonal IgG.
- MAR mouse anti-rat K
- the MAR Model EL 308; Bio-Tek Instruments, Inc., Burlington, VT) Serum and plasma samples were tested at 1:100 and 1:1000 dilution to achieve fibrosin concentrations in the linear portion of the standard curve. Plasma and serum fibrosin concentrations were calculated using the formula that relates O.D. 405 ("x") to pg protein/ml ("y”) , using the log-linear plot of the standard curve generated for each set of assays, and adjusted for dilution.
- mice In studies of murine schistosomiasis, C57BL/6NcrLBr female mice (18 to 20 g; Taconic Farms, Inc., Germantown, NY) were infected by the intraperitoneal injection of 35-50 cercariae of S. mansoni (Puerto Rican strain) suspended in 0.5 ml sterile saline as described above.
- mice For serum and plasma sampling, mice were individually ear tagged for identification, anesthetized by inhalation of methoxyflurane (Metofane, Pitman-Moore, Inc., Mundelein, IL) , and retro-orbital sinus blood was obtained into plain or heparinized hematocrit tubes (Arthur H. Thomas Co., Philadelphia, PA). The serum or plasma was retrieved after hematocrit centrifugation and was stored at -20 ⁇ C in 0.5 ml polypropylene vials (Brinkmann Instruments, Inc., Westbury, NY).
- each of three separately prepared rat anti-fibrosin Mabs IP8/C9, IIIG6/C7, and IIIA5/P8 detects a single 60 kP protein in serum-free conditioned medium from egg granuloma cultures and T cell hybridoma cultures (Fig. 27).
- Normal rat IgG reveals no protein bands by this method (results not shown) .
- the electrophoretic migration of the 60 kP protein corresponds to that of fibrosin (Prakash et al. , J. Immunol.
- mice Serum Levels of Fibrosin Peak at the Same Time the Granulomatous Inflammatory Response Peaks
- mice were infected with S. mansoni and were bled at regular intervals thereafter.
- Ten uninfected strain-, age- and sex-matched mice served as controls. All the plasma sample (stored at -20°C) were assayed simultaneously, and the results were confirmed in separate additional assays of selected samples.
- plasma fibrosin concentrations were in the normal range.
- fibrosin levels were above normal levels in almost all the mice.
- Fibrosin production by granuloma CP4 + lymphocytes is likely to be stimulated by egg antigens, and CD4 + lymphocyte hypersensitivity to these antigens is most vigorous at week 8 of infection. The hypersensitivity wanes thereafter and is considerably depressed at week 12.
- 2B3 is a biologically active, truncated fibrosin peptide that is based on the deduced amino acid sequence of a single open reading frame in a truncated fibrosin cDNA (clone 2B3) that we cloned from a murine cDNA library, also as described above.
- Monoclonal antibody was prepared, as described above, to heparin-purified murine fibrosin.
- Assays of Biological Activity Primary human dermal fibroblast cultures were prepared and propagated as described above, and assessed between passage 4 and 12. Fibroblast chemotaxis was assessed in modified Boyden chambers by published methods (see Wyler et al., J. Immunol. 188:478, 1977). Experiments using Boyden chambers were also performed, as described below, to assess the ability of COS cells transfected with human FsF-1 to stimulate the chemotaxis of human peripheral monocytes.
- Fibroblast collagen synthesis was measured by quantifying the incorporation of 3 H-proline into trichloroacetic acid-precipitated, collagenase-sensitive protein in fibroblast culture supernatants using a published microassay method (Diegelmann et al.. Anal. Biochem. (1990)). Collagen synthesis results were subsequently confirmed and extended by using HPLC to analyze the relative concentration of hydroxyproline and reference amino acids in hydrolysates of serum-free fibroblast-conditioned medium. For this purpose, fibroblasts suspended in antibiotic-containing Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum (DMEM-10) were grown to confluency in 100 mm diameter tissue culture dishes.
- DMEM Dulbecco's modified Eagle's medium
- Fibronectin and hyaluronan concentrations in serum-free, fibroblast-conditioned medium were determined by published methods. For these experiments, IO 5 fibroblasts suspended in DMEM-10 were seeded into each 16 mm diameter well of 24-well tissue culture plates and incubated at 37°C in 5% C0 2 -95% air atmosphere until the cell layer appeared confluent. The cultures were extensively washed, replenished with DMEM-0, and incubated for an additional 18-24 h, at which time stimuli were added to the cultures. Aliquots of conditioned medium were retrieved and stored at -20°C until tested.
- Mab recognizes an epitope within the 2B3 peptide that is also expressed in native fibrosin. Fibrosin has Chemotactic Properties that are
- Purified native fibrosin and 2B3 peptide are both chemotactic agents to fibroblasts when assessed in modified Boyden chambers (Fig. 31 panels A-C) .
- the addition of anti-fibrosin Mab markedly reduces this biological effect of purified native fibrosin (Fig. 31, panel C) . It therefore appears that the chemotactic domain, like the mitogenic domain, is contained in the 2B3 region.
- the optimal chemotactic concentration of the 2B3 peptide (10 nM range) is at least an order of magnitude higher than the optimal concentration of the native molecule (100 ⁇ M range) .
- a plasmid bearing a large fragment of human fibrosin cDNA (pBKCMVHFibrosinl) was purified from liquid cultures (QIAGEN plasmid preps) and transfected by lipofection into COS cells. The efficiency of the transfection was determined by a chromogenic reaction. As a negative control, COS cells were also transfected with plasmid lacking the fibrosin encoding insert. The supernatant was collected from the cells after 24 hours in culture under serum-free conditions. The assay for chemotaxis was carried out in Boyden chambers, which consist of lucite blocks that are separated into two chambers by a polycarbonate filter with 5 ⁇ m pores.
- Human peripheral monocytes were placed in one chambers and the supernatant collected from transfected COS cells was placed in the second chamber. The cells remained in the chamber for 90 minutes before the filters were harvested and stained. Cells were counted under high power magnification and the results (Fig. 43) were expressed as the average number of cells per high power field (HPF) . Cells transfected with the plasmid bearing the human FsF-1 encoding insert stimulated the chemotactic movement of monocytes.
- Fibronectin and hyaluronan are two matrix components that frequently are produced early in the course of fibrogenesis. Fibrosin stimulates fibroblasts to produce both of these macromolecules (Fig. 32, panel A and Fig. 32, panel B) . Since the addition of cycloheximide blocks the fibrosin-enhanced elaboration of fibronectin, this response depends on de novo protein synthesis rather than simply release of pre-formed fibronectin. Furthermore, the 2B3 peptide stimulates fibronectin synthesis and antifibrosin Mab blocks the stimulatory effect of the truncated peptide and native fibrosin (Fig. 35 panel C) .
- Fibrosin (optimal concentration 20 ⁇ g/ml) stimulates, in contact-inhibited fibroblast cultures, a net increase in the incorporation of 3 H-proline into collagenase-sensitive secreted protein (Table 3) .
- fibrosin Although fibrosin also increases total protein synthesis (collagenase-sensitive plus insensitive protein) , it stimulates a 40% increase above basal levels in the ratio of collagen-to-total protein synthesis when assessed with this assay (Table 3) . fibrosin
- molar concentration in fibroblast culture supernatants of hydroxyproline (hypro) that reflect collagen synthesis is expressed as a percentage of molar concentration of proline (pro) or leucine (leu) that reflect total protein synthesis.
- N 3.
- Hydroxyproline concentration (pM/ ⁇ g DNA) in fibroblast culture supernatants, expressed as percentage of concentration in supernatants of unstimulated (medium only) cultures.
- Ratio of hydroxyproline to proline concentration in supernatants of stimulated fibroblasts expressed as a percent of this concentration ratio of unstimulated cultures.
- Ratio of hydroxyproline to leucine concentration in supernatants of stimulated fibroblasts expressed as a percent of this concentration ratio for umstimulated cultures.
- in vivo fibrosin plays a role in the fibroblast recruitment, proliferation, and enhanced ECM production involved in scar formation, such as is observed in the setting of certain chronic inflammatory disorders, including schistosomiasis.
- FsF-1/FIBROSIN IS ANGIOGENIC in vivo Since the hepatic granulomas that form following S. mansoni infection also undergo neovascularization, we investigated whether fibrosin is also anhiogenic.
- Fibrosin purified as described above, or the 2B3 peptide, synthesized as described above, were incorporated into hydron pellets and implanted into the corneal stroma of rats. Induction of neovacsularization from the limbal vasculature was monitored for 7 days following implantation. Corneas were examined histologically for non-specific inflammation. Purified native fibrosin induced an angiogenic response in rat corneas without inciting an inflammatory reaction. The minimum amount of fibrosin required to elicit an angiogenic response (5 ng/implant) is comparable to the amount of bFGF, VEGF, or TNF ⁇ required to induce similar responses.
- the 2B3 peptide (maximum amount tested 2.5 ng) also elicited a distinct, inflammation-free angiogenic response.
- fibrosin has angiogenic properties in vivo with a potency similar to that of other well established angiogenic factors.
- the angiogenic activity of fibrosin derives from the same domain in the protein that signals fibrogenic responses, as revealed by experiemnts with the 2B3 peptide.
- the fibrogenic and angiogenic properties of fibrosin could account for the histopathy of liver fibrosis in experimental schistosomiasis.
- fibrosin could also play a role in formation of granulation tissue during would healing.
- FIBROSIN IS OVERPRODUCED BY SMOOTH MUSCLE CELLS IN THE BOWEL OF A CROHN'S DISEASE PATIENT
- FIBROSIN IS ABUNDANTLY PRODUCED BY RHEUMATOID SYNOVIOCYTE CULTURES
- FsF-1/Fibrosin can be immunopurified from the sera of patients, as described above (see “Gel Filtration Chromatography and Heparin Affinity Chromatography”). Furthermore, this immunopurified human serum fibrosin is biologically active in the fibroblast proliferation assay, as described above (see also Fig. 42) .
- the concentration of serum fibrosin is also elevated in patients with inflammatory bowel disease
- Fig. 38 is a series of photomicrographs of scleroderma cells cultured in MEM Eagle's Medium with 10% FCS. These experiments examined the effect of an antifibrosin antibody on the production of collagen by scleroderma cells.
- the cultured scleroderma cells were treated with 20 ⁇ g/ml of random IgG, or 20 ⁇ g/ml anti-fibrosin antibody for either one or two days, and stained with an antibody against type I collagen (Fig. 38) .
- Treatment with the anti-fibrosin antibody diminished the expression of type I collagen.
- the effect of conditioned medium on collagen expression was also investigated.
- fibroblasts were cultured as described and exposed to either conditioned medium from normal fibroblasts, conditioned medium from sclerodermal fibroblasts, or conditioned medium from sclerodermal fibroblasts that had been depleted with anti-fibrosin antibodies. The cells were then stained with an antibody against type I collagen. Conditioned medium from scleroderma cells stimulated collagen production, which was blocked by addition of anti-fibrosin antibodies to the conditioned medium (Fig. 39) . A similar observation was made for the production of fibronectin: conditioned medium from sclerodermal cells stimulated fibronectin production, which was blocked by addition of anti-fibrosin antibodies to the conditioned medium (Fig. 40) .
- overexpression of the nucleic acids of the invention can be used to isolate large quantities of FsF-1 polypeptides that are capable of efficiently stimulating fibroblast growth, proliferation and chemotaxis.
- the methods described herein can be used to generate synthetic or recombinant polypeptides that are capable of inhibiting one or more of the biological activities of the naturally occurring FsF-1 polypeptide.
- antagonistic peptides can be produced and tested in any of the assays described herein for the ability to neutraize the mitogenic and/or chemotactic activity of the naturally occurring polypeptide.
- the FsF-1 polypeptides of the invention will be admixed with a pharmaceutically acceptable carrier substance, e.g., physiological saline, and administered to a mammal, e.g., a human, suffering from a wound or a burn.
- a pharmaceutically acceptable carrier substance e.g., physiological saline
- the particular mode of administration is preferably topical.
- the dosage of polypeptide will vary, depending on such factors as the type and severity of the lesion, but will generally be at a dosage sufficient to stimulate adequate fibroblast proliferation and chemotaxis to the lesion site. A typical dosage range would be 1 ng to 10 mg of the polypeptide, and treatment can be repeated as deemed necessary to promote healing.
- the nucleic acids of the invention can be used therapeutically.
- Oligonucleotides which are antisense to FsF-1 mRNA can be utilized as an antifibrotic therapy.
- the method would involve introduction of the antisense oligonucleotide into lymphocytes in vivo.
- the antisense hybridizes with endogenous FsF-1 mRNA, interfering with translation of the protein, thereby reducing production of the polypeptide.
- Methods of antisense design and introduction into host cells are described, for example, in Weinberg et al., U.S. Patent No. 4,740,463. OTHER EMBODIMENTS
- the invention includes any protein which is substantially homologous to murine or human FsF-1 as well as other naturally occurring FsF-1 polypeptides. Also included are: allelic variations; natural mutants; induced mutants; chimeric polypeptides that include a FsF-1 polypeptide; proteins encoded by DNA that hybridizes under high stringency conditions (e.g., see Current Protocols in Molecular Biology, supra to a naturally occurring nucleic acid encoding FsF-1; and polypeptides or proteins specifically bound by antisera to FsF-1, especially by antisera specific to the 2B3 fragment of FsF-1.
- Preferred analogs of the invention include FsF-1 polypeptides (or biologically active fragments thereof) whose sequences differ from the naturally occurring FsF-1 polypeptide by amino acid sequence differences or by modifications that do not affect sequence, or by both.
- Analogs of the invention will generally exhibit at least 70%, preferably at least 80%, more preferably at least 90%, and most preferably at least 95% or even 99%, similarity with all or part of a naturally occurring FsF- 1 polypeptide.
- the length of comparison sequences will generally be at least 20 amino acids residues, and preferably, more than 40 amino acid residues.
- Differences in amino acid sequence can be by conservative amino acid substitutions, for example substitution of one amino acid for another of the same class (e.g., valine for glycine, arginine for lysine, etc.) or by one or more nonconservative amino acid substitutions, deletions, or insertions which do not destroy the analog's biological activity as measured by the assays described herein.
- Modifications include in vivo or in vitro chemical derivatization of polypeptides, e.g., acetylation or carboxylation.
- glycosylation e.g., those made by modifying the glycosylation patterns of a polypeptide during its synthesis and processing or in further processing steps, e.g., by exposing the polypeptide to glycosylating enzymes from cells that normally provide such processing, e.g., mammalian glycosylation enzymes.
- phosphorylated amino acid residues e.g., phosphotyrosine, phosphoserine, or phosphothreonine
- analogs that include residues other than naturally occurring L-amino acids, e.g., D-amino acids or non- naturally occurring or synthetic amino acids, e.g., ⁇ or ⁇ amino acids.
- Preferred analogs also include FsF-1 (or biologically active fragments thereof) which are modified for the purpose of increasing peptide stability, e.g., one or more desaturated peptide bonds, or non-peptide bonds. Alternatively, increased stability can be conferred by cyclizing the peptide molecule.
- plasmids pCR3MFibrosin; in TOPIOF'
- plasmid pcDSR ⁇ 29b/2B3; in DH5 ⁇
- plasmid pBKCMVHFibrosinl; in XLOLR
- the deposited material will be maintained with all the care necessary to keep it viable and uncontaminated for a period of at least five years after the most recent request for the furnishing of a sample of the deposited plasmid, and in any case, for a period of at least thirty (30) years after the date of deposit or for the enforceable life of the patent, whichever period is longer.
- Applicants' assignees acknowledge their duty to replace the deposit should the depository be unable to furnish a sample when requested due to the condition of the deposit.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Procédé permettant de repérer les sujets ayant une propension à la fibrose pathologique. Dans ce procédé, on prélève un échantillon chez un sujet présentant une maladie inflammatoire chronique et on met l'échantillon en contact avec un anticorps spécifique du facteur de stimulation des fibroblastes 1 (FsF-1), dans des conditions permettant la formation d'un immunocomplexe; toute augmentation dans le niveau relatif de l'immunocomplexe indique une propension à la fibrose pathologique. L'invention porte également sur les polypeptides FsF-1 et les anticorps spécifiques de ces FsF-1, ainsi que sur les séquences d'ADN codant ces polypeptides FsF-1.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU51772/96A AU5177296A (en) | 1995-02-28 | 1996-02-28 | Fsf-1 and the early detection of fibrosis |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39567495A | 1995-02-28 | 1995-02-28 | |
US08/395,674 | 1995-02-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996026953A1 true WO1996026953A1 (fr) | 1996-09-06 |
Family
ID=23564019
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1996/002727 WO1996026954A1 (fr) | 1995-02-28 | 1996-02-28 | Fsf-1 et la detection precoce des fibroses |
PCT/US1996/002726 WO1996026953A1 (fr) | 1995-02-28 | 1996-02-28 | FsF-1 ET LA DETECTION PRECOCE DES FIBROSES |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1996/002727 WO1996026954A1 (fr) | 1995-02-28 | 1996-02-28 | Fsf-1 et la detection precoce des fibroses |
Country Status (3)
Country | Link |
---|---|
AU (2) | AU5177296A (fr) |
IL (1) | IL117304A0 (fr) |
WO (2) | WO1996026954A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2302359A1 (fr) | 2009-09-24 | 2011-03-30 | Université De Reims Champagne-Ardenne | Spectroscopie de sérum en infrarouge pour l'évaluation non invasive de fibrose hépatique chez des patients souffrant d'une maladie chronique du foie |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993016715A1 (fr) * | 1992-02-24 | 1993-09-02 | New England Medical Center Hospitals, Inc. | Facteur 1 de stimulation de fibroblastes et detection anticipee de la fibrose |
-
1996
- 1996-02-28 WO PCT/US1996/002727 patent/WO1996026954A1/fr active Application Filing
- 1996-02-28 AU AU51772/96A patent/AU5177296A/en not_active Abandoned
- 1996-02-28 WO PCT/US1996/002726 patent/WO1996026953A1/fr active Application Filing
- 1996-02-28 AU AU51348/96A patent/AU5134896A/en not_active Abandoned
- 1996-03-10 IL IL11730496A patent/IL117304A0/xx unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993016715A1 (fr) * | 1992-02-24 | 1993-09-02 | New England Medical Center Hospitals, Inc. | Facteur 1 de stimulation de fibroblastes et detection anticipee de la fibrose |
Non-Patent Citations (17)
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2302359A1 (fr) | 2009-09-24 | 2011-03-30 | Université De Reims Champagne-Ardenne | Spectroscopie de sérum en infrarouge pour l'évaluation non invasive de fibrose hépatique chez des patients souffrant d'une maladie chronique du foie |
WO2011036267A2 (fr) | 2009-09-24 | 2011-03-31 | Universite De Reims Champagne Ardenne (U.R.C.A.) | Spectroscopie infrarouge de sérum pour évaluation non invasive de fibrose hépatique chez des patients atteints de maladies chroniques du foie |
Also Published As
Publication number | Publication date |
---|---|
AU5177296A (en) | 1996-09-18 |
AU5134896A (en) | 1996-09-18 |
WO1996026954A1 (fr) | 1996-09-06 |
IL117304A0 (en) | 1996-06-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0413908B2 (fr) | Fragment extracellulaire soluble du recepteur IFN-bêta 2/IL-6 humain, sa préparation et composition pharmaceutique le contenant | |
AU696764B2 (en) | Vascular endothelial growth factor 2 | |
EP0735818B1 (fr) | PROTEINES INFLAMMATOIRES MACROPHAGES MIP-3, MIP-4 ET MIP-1gamma | |
JP3375949B2 (ja) | 細胞障害性リンパ球成熟因子に対する抗体 | |
US20030124675A1 (en) | Isolated CDNA encoding tumor necrosis factor binding protein II, its purification, and vectors, hosts and processes using such cDNA | |
US8138312B2 (en) | Compositions for regulation of tumor necrosis factor-alpha | |
IE883523L (en) | Interleukin-1 Receptors | |
JPH10513049A (ja) | Eph様受容体リガンド | |
AU630496B2 (en) | Antagonists of gm-csf derived from the carboxyl terminus | |
WO1994009137A1 (fr) | Anticorps contre le recepteur du facteur de necrose de tumeurs de type 2 | |
WO1995024414A1 (fr) | Facteur-10 de croissance du fibroblaste | |
EP0361284B1 (fr) | Facteur de croissance pour des cellules T | |
WO1996018730A1 (fr) | Facteur de croissance prostatique | |
US7001595B2 (en) | Chemokine β-7 variants | |
JP2001500724A (ja) | T1レセプター様リガンドii | |
KR100382628B1 (ko) | 인터페론α/β결합단백질과이의제조및용도 | |
WO1996026953A1 (fr) | FsF-1 ET LA DETECTION PRECOCE DES FIBROSES | |
US6214968B1 (en) | Fibroblast stimulating growth factor 1 (FsF-1) and the early detection of fibrosis | |
WO1998008969A1 (fr) | Molecule accessoire soluble du recepteur de l'interleukine 1 | |
WO1993016715A1 (fr) | Facteur 1 de stimulation de fibroblastes et detection anticipee de la fibrose | |
US20040241639A1 (en) | Human tachykinin-related splice variants and compositions thereof | |
EP1602726A2 (fr) | Variants d'épissage associés à la tachykinine humaine et compositions les comprenant | |
JP2002514051A (ja) | T1レセプター様リガンドi | |
IL90488A (en) | Ifn-beta2/il-6 receptor its preparation and pharmaceutical compositions containing it |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase |